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age health care expenses that are also eligible for 
coverage under Medicaid is excepted from ERISA 
preemption Melior v Wasatch Crest Mut Ins 
Co, 2009 201 P.3d 1004, 622 Utah Adv Rep 20, 
2009 UT 5 Insurance c=> 1117(3), States c=* 18 41 
Group health insurance pohcy under employee 
benefit plans failed to comply witn statute forbid-
ding employee benefit plan from limiting oi exclud-
ing coverage or payment for any health care for an 
individual who would otherwise be covered or enti-
tled to benefits or services under terms of plan 
notwithstanding that plan specified that "services" 
covered by Medicaid were not excluded, where 
plan also precluded coverage for any expenses 
coveied by a government program Melior v 
Wasatch Crest Mut Ins Co, 2009, 201 P 3d 1004, 
622 Utah Adv Rep 20, 2009 UT 5 Insurance &* 
HEALTH CODE 
2484, Insurance c=> 2525(1), Laboi and Employ-
ment <&=> 567, Labor and Employment e=> 569(2; 
Terms of the group health insui ance pohcj un-
der employee welfare benefit plan did not operate 
to terminate insured's coverage when insured be-
came eligible foi Medicaid coverage, notwithstand-
ing ambiguity in policy that precluded coverage for 
any expenses covered by government program, but 
did not exclude "services" covered by Medicaid, 
policy evidenced attempt to comply with nominal 
requirements of law while at same time circum-
venting actual requirement of providing coverage 
regardless 
by Medicaid Melior v Wasatch Crest Mui Ins 
Co, 2009, 
2009 UT 
of whether beneficiary was also covered 
|201 P 3d 1004, 622 Utah Adv Rep 20, 
Insurance c=> 959vi ^  T abor and 
Employment <s=> 569(2) 
§ 26-19-19. Direct paymen t to the depar tment bf? third Darty 
Research Reference? 
ALR Library 
80 A L R 3rd 772, Personal Injur) Recover)' as 
Affecting Eligibility For, or Duty to Reimburse, 








UTAH FALSE CLAIMS ACT 
Title 
Definitions 
Kickbacks or bribes prohibited 
False statements or false representa-
tions relating to qualification of 
health institution or facility prohib-
ited—Felony 











Violation of other laws 
Medicaid fraud enforcement 
Investigations—Civil investigative de-
mands 
Limitation of actions—Civil acts ante 
dating this section—Civil burden of 
proof—Estoppel—Joint civil liabili-
ty—Venue 
§ 26-20-1. Title 
This chapter is known as the "Utah False Claims Act 
Laws 1981, c 126, § 19, Laws 2007, c 48, § 1, eff April 30, 20(1)7 
Historical and Statuto: 
Laws 2007, c 48, rewrote this section, which 
Notes 
formerly provided 
"This chaptei shall be known and may be cited 
as the 'False Clanns Act": 
Research References 
Encyclopedias 
100 Am Jur Proof of Facts 3d 1, Proof of a 
Claim Arising from Off-Label Use of Prescrip-
tion Medications 
§ 26-20-2. Definitions 
As used m tnis chapter. 
102 
UTAH FALSE CLAIMS ACT § 26-20-4 
(1) "Benefit" means the receipt of money goods, or any other thing of pecuniary value 
(2) "Claim" means any request or demand for money or property 
(a) made to any 
d) employee, officer, or agent of the state, 
(n) contractor with the state, or 
(in) grantee or other recipient, whether or not under contract with the state, and 
(b) if 
(l) any portion of the money or property requested or demanded was issued from or 
provided by the state, or 
(n) the state will reimburse the contractor, grantee, or other recipient for any portion 
of the money or property 
(3) "False statement" or "false representation" means a wholly or partially untrue state-
ment or representation which is 
(a) knowingly made, and 
(b) a material fact with respect to the claim 
(4) "Knowing" and "knowingly" 
(a) for purposes of criminal prosecutions for violations of this chapter, is one of the 
culpable mental states described in Subsection 26-20-9(1), and 
(b) for purposes of civil prosecutions for violations of this chapter, is the required 
culpable mental state as defined in Subsection 26-20-9.5(1) 
(5) "Medical benefit" means a benefit paid or payable to a recipient or a provider under a 
program administered by the state under 
(a) Titles V and XIX of the federal Social Security Act,1 
(b) Title X of the federal Public Health Services Act,2 
(c) the federal Child Nutrition Act of 1966 as amended by P.L 94-105, and 
(d) any programs for medical assistance of the state 
(6) "Person" means an individual, corporation, unincorporated association, professional 
corporation, partnership, or other form of business association 
Laws 1981, c 126, § 19, Laws 1986, c 46, § 1, Laws 2007, c 48, § 2, eff April 30, 2007 
142USCA § 701etseq and42USCA.§ 1396etseq 
242USOA § 300etseq 
Historical and Statutory Notes 
Laws 2007, c 48, rewrote this section, which his conduct is substantially certain to cause the 
formerly provided intended result 
"As used in ttos chapter "(4> '*Jedlca] b e n e f m e a n s » bene f i* Pa ,d o r 
r
 payable to a recipient or a provider under a pro-
"U) 'Benefit' means the receipt of money, goods, gram administered by the state undei Titles V and 
oi any other thing of pecuniary value XIX of the federal Social Security Act, Title X of 
«fo\ <*?oW «,+0+«^ *«t' ~~ <f«w ,awfiPO«+«+1^' the federal Public Health Services Act,the federal (2) False statement or false representation
 QMd NufcntiQn 1966 ^ j p L 
means a statement or representation which is ^ m ^ m s ^ ^ ^ ^ of 
knowingly and willfully made if the person making , v *. J ^ & 
the statement or representation has knowledge of
 U/_N m , , , , 
die falsity thereof (&) P e r s™ m e a n s *n ^dividual, corporation, J
 unincorporated association, professional corpora-
ls) 'Knowing' and 'knowingly* mean tnat a pei- tion, partnership, or other form of busmess associ-
son is aware of the nature of his conduct and that ation " 
§ 26-20-4. Kickbacks or bribes prohibited 
(1) For purposes of this section, kickback or bribe 
(a) includes rebates, compensation, or any other form of remuneration which is 
(l) direct or indirect, 
(u) overt or covert, or 
(ui) m cash or in kind, and 
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(b) does not include a rebate paid to the state under 42 U S C Sec 1396r-8 or any state 
supplemental rebates 
(2) A person maj not solicit, offer, pay, or receive a kickback or bribe in return for or to 
induce 
(a) the purchasing leasing or ordering of any goods or services for which payment is or 
ma\ be made in whole or m part pursuant to a medical benefit program, or 
(b) the referral of an individual to another person for the furnishing of any goods 01 
services for which payment is or may be made m whole or m part pursuant to a medical 
benefit program 
Laws 1981 c 120, § 19, Laws 1986, c 46, § 3, Laws 2007, c 48J § 3, eff April 30,2007 
Historical and Statutory Notes 
Laws 2007, c 48 repealed and reenacted this of goods or services for which payment is o* may 
section, wnich formerly provided be made in whole or m part pursuant to z medical 
_ benefit program, or pay or receive a rebate of ? fee 
A person may not solicit, offer pay, or receive a
 o r cha rgk for referring an individual to another 
kickbad or bribe m connection with the furnishing person fpi the furnishing of goods or services " 
§ 26-20-5. False s ta tements or false representat ions relat ing to qualification 
of hea l th inst i tut ion or facility prohibi ted-JFelony 
(lj A person may not knowingly, intentionally, or recklessly make, induce, or seek to 
induce the making of a false statement or false representation of a material fact with respect 
to the conditions or operation of an institution or facility m order that the institution or 
facility may qualify, upon initial certification or upon recertification, as a hospital, skilled 
nursing facility, intermediate care facility, or home health agency 
(2) A person who violates this section is guilty of a second degree felony 
Laws 1981, c 126, k 19, Laws 2007, c 48, § 4, eff April 30, 20 
Historical and Statutory Notes 
Laws 2007, c 48, in subsec (1) substituted "may 
not knowingly, intentionally, or recklessly" foi 
"shall not. Knowingly and willfully" 
§ 26-20-7. False claims for medical benefits Prohibited 
(1) A person may not make or present or cause to be made or presented to an employee or 
officer of the state a claim for a medical benefit 
(a) whicn is wholly or partially false, fictitious, or fraudulent, 
(b) for services wr3uch were not rendered or for items or materials which were not 
delivered, 
(c) which misrepresents the type, quality, or quantity of items or services rendered, 
(d) representing charges at a higher rate than those charged by the provider to the 
general pubhc 
(e) for items or services which the person or the provider knew were not medically 
necessary m accordance with professional^ recognised standards, 
(f) which has previously been paid, 
(gi for services also covered by one or more private sources when the person or pro^ idei 
knew of the private sources without disclosing thojse sources on the claim, or 
0.) where a provider I 
(1) unoundles a product, procedure or group of procedures usually and customanh 
provided or performed as a single billable product or procedure into artificial components 
ov separate procedures and 
(ii) bills for each component of the product, procedure or group of procedures 




UTAH FALSE CLAIMS ACT § 26-20-7 
Note 1 
(B) the aggregate billing for the components exceeds the amount otherwise billable 
for the usual and customary single product or procedure 
(2) In addition to the prohibitions m Subsection (1), a person maj not 
(a) fail to credit the state for payments received from other sources, 
(b) i ecover or attempt to reco\ er payment in violation of the provider agreement from 
(i) a recipient under a medical benefit program, or 
(nj the recipient's family, 
(c) falsify or alter with intent to deceive, any report or document required bj state or 
federal law, rule, oi Medicaid provider agreement, 
(d) retain any unauthorized payment as a result of acts described h} this section or 
(e) aid or abet the commission of any act prohibited by tins section 
Laws 1981 c 126, § 19, Laws 1986, c 46, § 5 Laws 1987 c 92, § 35 Laws 2007, c 48, * 5 eff April 
30 2007 
Historical and Statutory Notes 
Laws 2007 c 48, lewrote this section, which 
formerh provided 
"(1) No person may make or present oi cause to 
be made oi presented to an employee oi officer of 
the state a claim for a medical benefit, knowing the 
claim to be false, fictitious, oi fraudulent 
"(2) In addition, no pel son shall knowingly 
"(a) file a claim for a medical benefit foi services 
which vere not rendered oi foi items or materials 
vhich were not delivered 
"(b) file a claim for a medical benefit which 
misrepresents the type, quality, or quantity of 
items oi services rendered, 
"(c) file a claim foi a medical benefit represent-
ing cnarges at a highei rate than those charged by 
the pi ovidei to the general public, 
"(d) file a claim foi a medical benefit for items 
oi services winch the person or the provider knew 
were not medically necessary in accordance with 
professional^  recognized standards 
"(e) file a claim for a medical benefit which has 
jneviouslj been paid, 
"(f) fail to credit the state for payments received 
nom other sources, 
"(g) file a claim foi a medical benefit foi ser-
vices also covered by one or more private sources 
when the person or providei knew of the private 
sources without disclosing those sources on the 
claim, 
"(h) recover or attempt to recover payment 
from a recipient unaer a medical benefit program, 
or the recipient s familj in violation of the provider 
agreement, 
"(l) file a claim for a medical benefit where a 
provider divides an accepted multiple medical pro-
cedure into artificial components or single proce-
dures requesting full medical benefits for perform-
ing those component procedures as if the} had 
each been performed independently and at sepa-
rate times, 
"0) falsify or alter with intent to deceive, any 
repoH or document required by state or federal 
law, rule, oi medicaid providei agreement, 
"(k) retain any unauthorized payment as a re-
sult of acts described by this section, or 
"(I) aid or abet the commission of any acr pro-
hibited by this section" 
In general, 
False claims act intent to cause govern-
ment payment of false claim prr\ ate enti-
Umted States Supreme Court 
ties using government funds, see Allison 
Engine Co Inc A I S ex rei Sanders 
2008 128 SCt 2123, 170 LEd2d 1030 
Notes of Decisions 
Jurisdiction 1 
1 Jurisdiction 
Exeicise of fedeial jurisdiction in State of 
Utahs Medicaid reimbursement action against 
fr*ug manufacturei which manufacturei had ie-
moved nom state court on federal-question 
pound* would disturb congressional!v appioved 
balance of federal and state judicial responsibili-
ties requu'ing grant of states lemand motion 
even though exercise of federal jurisdiction would 
not atnact hoide of oneni&l filing's, no actualh 
disputed, substantial fedei al question was present-
ed federal preemption did not applj, and no cleai 
rule existed justifying removal of state Medicaid 
reimbursement actions Utah v Eh Lilh and Co 
2007 509 F Supp 2d 1016 Removal Of Cases c=» 
19(1) Remo\ al Of Cases o 25(1) 
Ko actually disputed, substantial fedeial ques-
tion was presented in State of Utahs Medicaid 
i eimbursement action against drug manufacturer, 
so as to warrant removal on that ground fedeia1 
issues were not essential to a dedication of state s 
claims, grounded on its False Claims Act and 
common law manufacture!'s raising of federal 





tion mere presence of federal standards such as 
"medically accepted indications" did not confei ju-
risdiction absent federal remedj and Congress 
had specifically required states to seek reimbur^e-
HEALTH CODE 
ment from liable thiio parties without providing 
such remedy Utah \ Eb Lilly ano Co , 2007, 509 
F Sipp 2d 1016 Removal Of Cases c=* 19(1), Re 
movjal Of Cases c^ 25(1; 
§ 26-20-9. Criminal penalt ies 
(l)(a) Except as provided m Subsection (l)(b) the culpable mental state required for a 
criminal violation of this chapter is knowingly, intentionally, or recklessly as defined in 
Section 76-2-103 
(b) The culpable mental state required for la criminal violation of this chapter for 
kickbacks and bribes under Section 26-20-4 is knowingly and intentionally as defined in 
Section 76-2-103 
(2) The punishment for a criminal violation of jany provision of this chapter, except as 
pi ovided under Section 26-20-5 is determined by the cumulative value of the funds or other 
benefits received or claimed m the commission of all violations of a similar nature, and not by 
each separate violation 
(3) Punishment for criminal violation of this chapter, except as provided under Section 
26-20-5, is a felony of the second degree, felony of the third degree class A misdemeanor, or 
class B misdemeanor based on the dollar amoanti as nreannbed by Subsection 76-6-412(1) 
for theft of property and services 
Laws 1986, c 46, § 6, Laws 2007, c 48, § 6, eff April 30,|2007 
Historical and Statutory Notes 
Laws 2007, c 48 rewrote this section, which 
formerly pi ovided 
"(1) The punishment for violation of any provi-
sion of this chapter, except as provided under 
Section 26-20-5, is determined by the cumulative 
value of the funds or other benefits received or 
claimed m the commission of all violations of a 
similar nature, and not bj each separate violation 
"(2) Punishment for violation of this chapter, 
except as provided under Section 26-20-5, is as 
follows 
"(aj as a felonj of the second degree if the 
cumulative value of the funds or other benefits 
rectei\ed or claimed in violation of this chapter 
exieeds Si,000, 
T(b) as a felony of the third degree if the cumu-
lative value of the funds oi other benefits received 
or claimed m violation of this chapter exceeds $250 
but does not exceed $1,000, 
j'(c) as a class A misdemeanor if the cumulative 
value of the funds or other benefits received or 
claimed in violation of this chapter exceeds $100 
but does not exceed $250, or 
((d) as a class B misdemeanor if the cumulative 
value of the funds or other benefits received or 
claimed in violation of this chantei does not exceed 
$100 " 
United States Supreme Court 
False claims. 
False claims act intent to cause govern-
ment payment of false claim, private enti-
ties using government funds, see Allison 
Engine Co., Inc v U S ex rel Sanders, 
2008, 128 SCt 2J.23, 170 LEd2d 1030 
§ 26-20-9.5. Civil penal t ies 
Q) The culpable mental state required for a cifnl violation of this chapter is "knowing'" or 
"knowingly' which* 
(a) means that person, with respect to mfornjauon 
d) has actual knowledge of the information, 
'n) acts m deliberate ignorance of the trutlp or falsity of the information, or 
(in) acts m l eckless disregard of the truth I 
(b) does not require a specific intent to defraud 
C; Any person who violates tins chapter shall 
pi ovided by lav, be required to 
(a) make full and complete restitution to the 
because oi the person s violation of this chapter], 
106 
pr falsity of the information, and 
i 
m all cases, m addition to other penalties 
state of all damages that the state sustains 
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(b) pa} to the state its costs of enforcement of this chaptei in that case including but not 
limited to the cost of investigators, attorneys, and othei public employees as determined b> 
the state, and 
(c) pay to the state a civil penalty equal to 
U) three times the amount of damages that the state sustains because of the pei son's 
violation of this chapter, and 
(n) not less than $5 000 or more than SI0,000 for each claim filed or act done m 
violation of this chapter 
(3) Any civil penalties assessed under Subsection (2) shall be awarded bj the court as part 
of its judgment m both criminal and civil actions 
(4) A criminal action need not be brought against a person m order for that person to be 
civilly liable under this section 
Laws 1986, c 46, § 7, Laws 1987, c 92, § 36, Laws 2007 c 48 § 7 efi April 30 2007 
Historical and Statutory Notes 
Laws 2007, c 48, rewrote this section, which "(c) may he lequired, in the discretion of the 
formerly provided court to pay to the state a civil penalty not to 
"(1) Any person who violates this chapter shall e x c e e d three times the amount of value improperly 
in addition to other penalties provided by lav, be c l a i m e d o r received as a medical benefit or 
subject to the following civil penalties (((d) may be required, m the discretion of the 
"(a) in all cases, shall be required to make full c o u r t ' to paj to the state a civil penalty of up to 
and complete restitution to the state of all medical $>2>000 fo1 e a c h d a m nled °J act done in violation 
benefits impropei ly obtained, of tills c h a P t e l 
"(h) m all cases, shall be required to pay the "W Any civil penalties assessed undei Subsec-
state its costs of enforcement of this chapter m t l of M sha11 b e awarded bj the court as part of its 
that case, including but not limited to the cost of judgment in both criminal and civil actions 
investigators attorneys, and other pubhc employ- "(3) A criminal action need not be brought 
ees, as determined by the Bureau of Medicaid against a person in ordei foi that person t-o be 
Fraud, civilly liable under this section " 
United States Supreme Court 
False claims, ties using government funds, see Allison 
False claims act, intent to cause govern- Engine Co, Inc v U S ex rel Sanders, 
ment payment of false claim, private enti- 2008, 128 S Ct 212S 170 LEd2d 1030 
§ 26-20-12. Violation of o ther laws 
(1) The provisions of this chapter are 
(a) not exclusive, and the remedies provided for in this chapter are in addition to any 
other remedies provided for under 
d) any other applicable law, or 
(li) common law, and 
(b) to be liberally construed and applied to 
(i) effectuate the chapter's remedial and deterrent purposes and 
(n) serve the public interest 
(2) If any provision of this chapter or the application of this chaptei to am person or 
circumstance is held unconstitutional 
(a) the remaining provisions of tins chaptei shall not be affected and 
(b) the application of this chapter to other persons or circumstances shall not be affected 
Laws 1986, c 46 § 9, Laws 2007, c 48 * 8 eff Apnl 30 2007 
Historical and Statutory Notes 
Laws 2007 c 48 repealed and reenacted this "This chaptei shall not be construed to p^onibit 
section, which formerly provided or limit an action against a person foi violation of 
an> other law ' 
107 
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§ 26-20-13. Medicaid fraud enforcement 
(1) This chapter shall be enforced m accordance with this section 
(2' The department io l esponsible for 
(a)Ci; im estiganng and prosecuting suspected civil violations of this chapter, or 
{ii) referring suspected civil violations of this chapter to the attorney general for 
investigation and prosecution and 
(b) piompth lef erring suspected criminal violations cff this chapter to the attorney 
general foi criminal investigation and prosecution 
(3) The attorney geneialhas 
(a) concurrent jurisdiction with the department for ln+estigatine and prosecuting sus-
pected civil violations of this chapter, and 
(b) exclusive jurisdiction to lm estigate and prosecute all suspected criminal violations of 
this chaptei 
(4) The department and the attorney general share concurrent civil enforcement authority 
under tins chapter and mav enter into an interagency agreement regarding the investigation 
and prosecution of ^ lolauons of this chapter in accordance with this section, the requirements 
of Title XIX of the federal Social Security Act3, and applicable federal regulations 
(5) Any violation oi this chapter which comes to the attention of any state government 
officei or agency shall be leportecl to the attorney general or the department All state 
government officers and agencies shall cooperate with apd assist m any prosecution for 
violation of thib chapter 
Lavs 2000 c 310, * 2 eft Ma\ 1, 2000 Laws 2007, c 4S § 9, eff jApril 30, 2007 
1 41 U S> C A * 13% et sea 
Historical and 
Laws 2007, c 4S rewrote this section, which 
formerly provided 
"(1) This chaptei shall be enforced in accor-
dance with tins section 
"(2) The department shall be responsible for 
"(a) investigating and piosecutmg all civil viola-
tions of this chapter and 
"(b) promptly referring suspected criminal viola-
tions of this chaptei to the atton^ general for 
criminal investigation and prosecution 
"(3) The attorney general shall be responsible 
foi 
Statutory Nbtes 
"(a) investigating criminal violations of this 
chaptei thai are reported to the attorney general 
b\ the department or others 
"(b) promptly referring probable civil violations 
of this chaptei that are not related to a criminal 
investigation or prosecution to the department for 
civil investigation and prosecution, and 
"(c) prosecuting criminal violations of this chap-
tei 
"(4) The department and the attorney general 
ma^  enter into an interagency agreement regard-
ing the investigation and prosecution of violations 
of this chaptei m accordance with this section, the 
l equii ements of Title XIX of the federal Social 
Security Alct and applicable federal regulations" 
Notes of Decisions 




1 First amendment 
Nemologisi wnv v>a*> cnmmalh investigated and 
pi osecuted fr Utah «* Medicaid Fraud Conta ol Unit 
<MFCU> foi 'upcodmg' ie the practice of m> 
pioperh billing Medicaid foi a more expensne 
semce than vas actualh provided to the patient 
failed to pi oduce sufficient e\ idence that officials 
veie substantially motivated as a response to hei 
exercise of constitutionalh protected conduct, oi 
were e\en ava^e of such conduct as would suppoit 
First Amendment retaliation claim Becker v 
Ilroll 2004, 340 F Supped 1230, affirmed m part, 
lexei'sed m part and remanded 494 F3d 904, on 
lemand 2009 WL 819373 Constitutional Law ®=> 
1171, States o 79 
2 Immunitv 
Utah s Governmental Immunitv Act ban ed libel 
claim bi ought by neurologist who v>as cnmmalh 
investigated and prosecuted by Utah's Medicaid 
Fraud Gdntrol Unit (MFCU) foi "upcodmg,' I e, 
the practice of improper^ billing Medicaid for a 
more expensive service than was actually provided 
to the patient against MFCU officials, based solely 
upon publication of annual report on MFCU's web-
site vhere neurologist failed to produce evidence 
sufficient to support a finding of fraud oi malice in 
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tue publication of report Beckei \ Kioll 2004 
040 FSupp2d 1230 affirmed in pait leversed m 
ngrt and remanded 494 F 3d 904, on remand 2009 
V/L S1Q373 Libel And Slandei c=> 51(5) 
Genuine issue of material fact existed as to 
v hethei alleged m ongful conduct of state officials 
oceuned while they were acting in administrative 
and investigative capacities, precluding summary 
judgment for officials on basis of absolute lmmum-
n m erul rights action against them undei 
$§1933 Beckei v Kioll 2004, 340 FSupp2d 
1<?30 affirmed in part, reversed m part and re-
manded 494 F 3d 904 on remand 2009 WL 819373 
Fedeial Civil Piocedure c=> 2491 5 
3 Malicious prosecution 
Neurologist who was nevei arrested or incal cer-
ated in connection with the filing of criminal 
charges of alleged Medicaid fraud was not seized 
within meaning of Fourth Amendment, as required 
ror constitutional tort of malicious prosecution un-
der §§ 1983 Becker -\ Kroll, 2007, 494 F 3d 904, 
on remand 2009 WL 819373 Arrest e* 68(4) 
Civil Eights e= 1088(5) 
Genuine issue of material fact existed as to 
\\ hethei officials of Utah's Medicaid Fraud Conuol 
Unit (MFCU) knowingly targeted neurologist for 
prosecution without sufficient basis to believe there 
was probable cause she committed a crime, pre-
cluding summary judgment for officials on neurolo-
gist's §§ 1983 malicious prosecution claim, based 
on investigation and prosecution of her foi "upcod-
uig" I e, the practice of improperly billing Medic-
aid for a more expensive service than was actually 
provided to the patient Becker v Kroll, 2004, 340 
F Supp 2d 1230, affirmed m part, reversed in part 
and remanded 494 F 3d 904 on remand 2009 WL 
819373 Federal Civil Procedure &=> 2491 5 
Neurologist's §§ 1983 malicious prosecution 
claim against officials of Utah's Medicaid Fraud 
Control Unit (MFCU), based on investigation and 
pi osecution of neurologist for "upcoding' I e the 
practice of improperly billing Medicaia for a mo^ e 
expensive service than wras actually provided to the 
patient, would be reviewed undei due process stan-
dara of the Fourteenth Amendment rather than 
leasonableness standard of the Fourth Amend-
ment, where neurologist was never incarcerated 
Becker v Kroll 2004, 340 F Supp 2d 1230 af-
firmed in part reversed in part and remanded 494 
F 3d 904 on remand 2009 WL 819373 Constitu-
tional Law c=> 4527(2), Searches And Seizures c= 
23 States c= 79 
State trial court's independent finding of proba-
ble cause was not fatal to neurologist's §§ 1983 
malicious prosecution claim against officials of 
Utah's Medicaid Fraud Control Unit (MFCU), 
based on investigation and prosecution of neurolo-
gist foi "upcodmg," l e, the practice of improperly 
billing Medicaid foi a more expensive service than 
was actually provided to the patient Becker v 
Kroll, 2004, 340 F Supp 2d 1230, affirmed in pan, 
reversed in part and remanded 494 F 3d 904 on 
remand 2009 WL 819373 Civil Rights o 1088(5) 
4 Subpoena 
State officials' copying of neurologist's medical 
records through use of a subpoena in connection 
with investigation and prosecution of her for "up-
coding,' l e, the practice of improperly billing for a 
more expensive service than was actually provided 
to the patient, did not violate neurologist's Fourth 
Amendment rights although officials' use of sub-
poena did not comply with state statutes, where 
use of subpoena did not invoke same protections as 
use of a warrant, given that neurologist read sub-
poena and understood that she could either pro-
duce her records immediately or appear m person 
a few days latei Becker* \ Kroll, 2004, 340 
F Supp 2d 1230, affirmed in part, reversed in part 
and remanded 494 F 3d 904, on remand 2009 WL 
819373 Searches And Seizures e=» 75 
§ 26-20-14. Investigations—Civil investigative demands 
(1) The attorney general may take investigative action under Subsection (2) if the attorney 
general has reason to believe that 
(a) a person has information or custody or control of documentary material relevant to 
the subject matter of an investigation of an alleged violation of this chapter, 
(b) a person is committing, has committed, or is about to commit a violation of this 
chapter, oi 
(c) it is m the public interest to conduct an investigation to ascertain whether or not a 
person is committing, has committed, or is about to commit a violation of this chapter 
(2) In taking investigative action, the attorney general may 
(a) require the person to file on a prescribed form a statement m writing under oath or 
affirmation describing 
(O the facts and circumstances concerning the alleged violation of tins chapter, and 
(n) othei information considered necessary by the attorney general, 
(b) examine under oath a person in connection with the alleged violation of tins chapter, 
and 
(c) in accordance with Subsections (7) through (18) execute m writing, and serve on the 
person, a civil investigative demand requiring the person to produce the documental 
matenal and permit inspection and copying of the material 
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(3; The attorney general may not release or disclose information that is obtained under 
Subsection (2)(a) or (b), or any documentary material or other record derived from the 
information obtained under Subsection (2)(a) or (b)J except: 
(a) by court order for good cause shown; 
(b) with the consent of the person who provided the information; 
(c) to an employee of the attorney general or the department; 
(d) to an agency of this state, the United States, or another state; 
(e) to a special assistant attorney general representing the state in a civil action; 
(f) to a political subdivision of this state; or 
(g) to a person authorized by the attorney general to receive the information. 
(4) The attorney general may use documentary material derived from information obtained 
under Subsection (2)(a) or (b), or copies of that material, as the attorney general determines 
necessary in the enforcement of this chapter, including presentation before a court. 
(5)(a) If a person fails to file a statement as required by Subsection (2)(a) or fails to submit 
to an examination as required by Subsection (2)(b), the attorney general may file in district 
court a complaint for an order to compel the person to within a period stated by court order: 
(i) file the statement required by Subsection (2)(a); or 
(ii) submit to the examination required by Subsection (2)(b). 
(b) Failure to comply with an order entered under Subsection (5)(a) is punishable as 
contempt. 
(6) A civil investigative demand must: 
(a) state the rule or statute under which th|e alleged violation of this chapter is being 
investigated; 
(b) describe the: 
(i) general subject matter of the investigation; and 
(ii) class or classes of documentary material to be produced with reasonable specificity 
to fairly indicate the documentary material demanded; 
(c) designate a date within which the documentary material is to be produced; and 
(d) identify an authorized employee of the attorney general to whom the documentary 
material is to be made available for inspection and copying. 
(7) A civil investigative demand may require disclosure of any documentary material that is 
discoverable under the Utah Rules of Civil Procedure. 
(8) Sendee of a civil investigative demand may be made by: 
(a) delivering an executed copy of the demand to the person to be served or to a partner, 
an officer, or an agent authorized by appointment or by law to receive service of process on 
behalf of that person; 
(b) delivering an executed copy of the demand to the principal place of business in this 
state of the person to be served; or 
(c) mailing by registered or certified mail an executed copy of the demand addressed to 
the person to be served: 
(i) at the person's principal place of business in this state; or 
(ii) if the person has no place of business 
or place of business. 
(9) Documentary material demanded in a civil investigative demand shall be produced for 
inspection and copying during normal business hours at the office of the attorney general or 
as agreed by the person served and the attorney general. 
(10) The attorney general may not produce for inspection or copying or otherwise disclose 
the contents of documentary material obtainep pursuant to a civil investigative demand 
except: 
(a) by court order for good cause shown; 
(b) with the consent of the person who produced the information; 
(cj to an employee of the attorney general or the department; 
(d) to an agency of this state, the United States, or another state; 
lid 
in this state, to the person's principal office 
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(e) to a special assistant attorney general representing the state in a civil action: 
(f) to a political subdivision of this state; or 
(g) to a person authorized by the attorney general to receive the information. 
(ll)(a) With respect to documentary material obtained pursuant to a civil investigative 
demand, the attorney general shall prescribe reasonable terms and conditions allowing such 
documentary material to be available for inspection and copying by the person who produced 
the materia] or by an authorized representative of that person. 
(b) The attorney general may use such documentary material or copies of it as the 
attorney general determines necessary in the enforcement of this chapter, including 
presentation before a court. 
(12) A person may file a complaint, stating good cause, to extend the return date for the 
demand or to modify or set aside the demand. A complaint under this Subsection (12) shall 
be filed in district court and must be filed before the earlier of: 
(a) the return date specified in the demand; or 
(b) the 20th day after the date the demand is served. 
(13) Except as provided by court order, a person who has been served with a civil 
investigative demand shall comply with the terms of the demand. 
(I4)(a) A person who has committed a violation of this chapter in relation to the Medicaid 
program in this state, or to any other medical benefit program administered by the state has 
submitted to the jurisdiction of this state. 
(b) Personal service of a civil investigative demand under this section may be made on 
the person described in Subsection (14)(a) outside of this state. 
(15) This section does not limit the authority of the attorney general to conduct investiga-
tions or to access a person's documentary materials or other information under another state 
or federal law, the Utah Rules of Civil Procedure, or the Federal Rules of Civil Procedure. 
(16) The attorney general may file a complaint in district court for an order to enforce the 
civil investigative demand if: 
(a) a person fails to comply with a civil investigative demand; or 
(b) copying and reproduction of the documentary material demanded: 
(i) cannot be satisfactorily accomplished; and 
(ii) the person refuses to surrender the documentary material. 
(17) If a complaint is filed under Subsection (16), the court may determine the matter 
presented and may enter an order to enforce the civil investigative demand. 
(18) Failure to comply with a fmal order entered under Subsection (17) is punishable by 
contempt. 
Laws 2007, c. 48, § 10, eff. April 30, 2007. 
§ 26-20-15. Limitation of actions—Civil acts antedating this section—Civil 
burden of proof—Estoppel—Joint civil liability—Venue 
(1) An action under this chapter may not be brought after the later of: 
(a) six years after the date on which the violation was committed; or 
(b) three years after the date an official of the state charged with responsibility to act in 
the circumstances discovers the violation, but in no event more than ten years after the 
date on which the violation was committed. 
(2) A civil action brought under this chapter'may be brought for acts occurring prior to the 
effective date of this section if the limitations period set forth in Subsection (1) has not lapsed. 
(3) In any civil action brought under this chapter the state shall be required to prove by a 
preponderance of evidence, all essential elements of the cause of action including damages. 
(4) Notwithstanding any other provision of law, a final judgment rendered in favor of the 
state in any criminal proceeding under this chapter, whether upon a verdict after trial or upon 
a plea of guilty or nolo contendere, shall estop the defendant from denying the essential 
elements of the offense in any civil action under this chapter which involves the same 
transaction. 
I l l 
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(5) Civil liability under this chapter shall be joint and several for a violation committed by 
two or more persons 
(6) Any action brought b} the state under this chapter shall be brought m district court m 
Salt Lake County or m an} county where the defendant resides or does business 








HEALTH CARE FACILITY LICENSING 





Duties of committee 
Criminal background check and Li-
censing Information System check 
Operating facility in violation of chap-







Integrated health systems, contract negotiation 
standards, see § 13-5b-103 
Medical records requests for copies, see 
§ 26-6b-3 4 
-21-25 
Requirement for hospitals to provide 
statements of itemized charges to 
patients 
Licensing of non-Medicaid nursing 
care facility beds 
Piohibition against bed banking by 
nursing care facilities for Medicaid 
reimbursement 
Patient identity protection 
Municipal land use development, defining resi-
dential facility for persons with a disability, see 
§ 10-9a-103 
Law Review and Journal Commentaries 
Assisted living m Utah A bnef overview foi 
consumers Mary Jane Ciccarello, Joanne Wetzler, 
19 Utah B J 24 (Feb 2006) 
§ 26-21-1. Title 
Cross Reiejrences 
Disabilities, residences for certain persons, see 
§ 17-27a-519 
Human services licensing, exclusions, see 
§ 62A-2-110 
Residences for persons with a disability, see 
10-9a-520 
Standardized health benefit plan cards , see 
J 31A-22-636 
§ 26-21-2. Definitions 
As used in this chapter 
(1) "Abortion clinic'' means a facility, othei trian a general acute or specialty hospital, that 
performs abortions and provides abortion servic 







(g) transferring, and 
(h) self-administration of medication 
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OTSUKA AMERICA, INC.; 
PFIZER, INC.; 
QUALITEST PHARMACEUTICALS, INC.; 
SCHERING-PLOUGH CORPORATION; 
SCHWARZ PHARMA USA HOLDINGS, 
INC; 
TARO PHARMACEUTICALS USA, INC.; 
UPSHER-SMITH, INC.; and 
WYETH, INC.; 
Defendants. 
Plaintiff, the State of Utah (hereinafter "Plaintiff' or "the State"), by and through its 
Attorney General Mark L. Shurtleff, hereby complains of the above-named Defendants and 
alleges, on information and belief, the following: 
INTRODUCTION 
1. The Defendants have engaged in false, misleading, wanton, unfair, and deceptive acts and 
practices in the pricing and marketing of their prescription drug products. The 
Defendants' fraudulent pricing and marketing of their prescription drugs have caused the 
State's Medicaid program ("Utah Medicaid") to pay grossly excessive prices for the 
Defendants' prescription drugs. Utah Medicaid is administered by the Division of Health 
Care Financing within the single state agency, the Utah Department of Health. 
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Fair and honest drug pricing is a matter of great importance to the State and its citizens. 
Expenditures by Utah Medicaid for prescription drug reimbursement have increased 
dramatically in the past several years as a result, in part, of Defendants' fraudulent pricing 
scheme, Each year Utah Medicaid spends tens of millions of dollars on prescription 
drugs. In fiscal year 2005 alone, Utah Medicaid spent $2(1)7.6 million on prescription 
drugs. Significant increases in prescription drug costs in: 
a health care funding crisis within the State that requires | 
between the Defendants and the State. 
recent years have contributed to 
[action to ensure fair dealing 
The State is accountable to its citizens and taxpayers for how it spends limited State 
resources, and it is obligated to pursue any party whose unlawful conduct has led to the 
excessive expenditure of State funds. Consequently, the State, by and through its Attorney 
General, brings this action to recover amounts overpaid for prescription drugs by Utah 
Medicaid, including both pharmacy-dispensed and physician-administered drugs, as a 
result of the fraudulent and wanton conduct of Defendants. 
This lawsuit seeks legal redress for the fraudulent and wanton marketing and pricing 
conduct of Defendants, who have profited from their wrongful acts and practices at the 
expense of the State. 
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JURISDICTION AND VENUE 
5. Jurisdiction over the subject matter of this cause of action is based upon the Utah False 
Claims Act, Title 26, Chapter 20 of the Utah Health Code, which provides remedies to 
redress Defendants' actions under Utah Code Annotated § 26-20-1 et seq. 
6. Personal jurisdiction over these Defendants is proper under the Utah Long Arm Statute as 
codified in §§ 78-27-22 and 78-27-24 of the Utah Code Annotated. 
7. Venue is proper in the Third Judicial District and Salt Lake County pursuant to Utah Code 
Annotated § 78-13-7 in that the false or fraudulent Utah Medicaid claims caused to be 
filed by Defendants' unlawful acts were filed in Salt Lake County with the State of Utah, 
its departments, agencies, instrumentalities and contractors. 
8. This case alleges causes of action which arise exclusively under Utah law and not the laws 
of the United States. To the extent that federal laws are implicated, the State disavows 
such intent. Specifically, the State makes no claim for reimbursement of Medicare Part B 
co-payments for udual eligible5' individuals. 
PARTIES 
9. Plaintiff is the State of Utah. The Utah Attorney General is authorized to initiate and 
maintain this action pursuant to Utah Code Annotated § 67-5-1 (18). 
10. The Defendants listed in paragraphs 11 through 39 are engaged in the business of 
manufacturing, distributing, marketing and/or selling prescription drugs that are 
reimbursed by Utah Medicaid. A comprehensive analysis is currently in process to 
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identify each Defendant's prescription drugs reimbursed bV Utah Medicaid for which a 
claim is made in this litigation; however, a few representative examples are listed in the 
attached Exhibit A. 
corporation with its principal 
Defendant Apotex 
11. Defendant Apotex Corporation. ("Apotex") is a Delaware!« 
place of business located at 1776 Broadway Suite 1800, New York, NY 10019. Apotex 
Corporation is a wholly-owned United States subsidiary of Apotex, Inc., a Canadian 
corporation with its principal place of business located at) 150 Signet Drive, Weston, 
Toronto, Ontario, Canada M9L 1T9. 
The Baxter Defendants 
12. Defendant Baxter International, Inc. ("Baxter International") is a Delaware corporation 
with its principal place of business located at One Baxter Parkway, Deerfield, EL 60015-
4633. 
13. Defendant Baxter Healthcare Corporation ("Baxter Healthcare"), a wholly-owned 
subsidiary of Baxter International, Inc, is a Delaware corporation with its principal place 
of business located at One Baxter Parkway, Deerfield, 1% 60015. 
The Boehringer Defendant^ 
14. Defendant Boehringer Ingelheim Corporation ("Boehringer") is a corporation organized 
under the laws of Nevada with its principal place of business located at 900 Ridgebury 
Road, Ridgefield, CT 06877, and is the parent company of Roxane, BIPI, and Ben Venue. 
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15. Defendant Roxane Laboratories, Inc. ("Roxane"), a subsidiary of Boehringer Ingelheim 
Corporation, is a Delaware corporation with its principal place of business located at 1809 
Wilson Road, Columbus, OH 43228-9579. 
16. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. ("BDPF'), a subsidiary of 
Boehringer Ingelheim Corporation, is a Delaware corporation with its principal place of 
business located at 900 Ridgebury Road, Ridgefield, CT 06877. 
17. Defendant Ben Venue Laboratories, Inc. ("Ben Venue"), a subsidiary of Boehringer 
Ingelheim Corporation, is a Delaware corporation with its principal place of business 
located at 300 Northfield Road, Bedford, OH 44146. 
18. Boehringer, Roxane, BIPI and Ben Venue (collectively "the Boehringer Defendants") are 
diversified healthcare companies that individually, and/or in combination with one 
another, engage in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agencies nationwide. 
Defendant Mallinckrodt Inc. 
19. Defendam Mallinckrodt Inc. is a Delaware corporation. Its headquarters are located at 675 
McDonnell Boulevard, Hazelwood MO 63042. Mallinckrodt Inc. is the U.S. subsidiary of 
Covidien Ltd., a Bermuda corporation with its principal place of business located at 131 
Front Street, Hamilton HM 12, Bermuda, 
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1020 First Avenue, P.O. Box 
Defendant CSL Behring 
20. Defendant CSL Behring ("CSL"), formerly known as ZLB| Behring, is a Pennsylvania 
corporation with its principal place of business located at 
61501, King of Prussia, PA 19406. CSL Bearing is a wholly-owned subsidiary of CSL 
Limited, an Australian corporation with its principal plac^ of business located at 45 Poplar 
Road, Parkville Victoria 3052, Australia. 
Defendant Forest 
21. Defendant Forest Laboratories, Inc. ("Forest") is a DelaWare cornoration with its principal 
place of business located at 909 Third Avenue, New York, NY 10022-4731. 
Defendant Morton Grove 
22. Defendant Morton Grove Pharmaceuticals, hie. ("Mortoii") is an Illinois corporation with 
its principal place of business located at 6451 W Main Sftreet, Morton Grove, IL 60053. 
Defendant Mutual 
23. Defendant Mutual Pharmaceutical Company, hie. ("Mutual") is a Pennsylvania 
corporation with its principal place of business located it 100 Orthodox Street, 
Philadelphia, PA 19124. 
• Novartis Defendant 
24. Defendant Novartis Pharmaceuticals Corporation ("Nojartis") is a Delaware corporation 




25. Defendant Otsuka America, Inc ("Otsuka") is the US holding company of Otsuka 
Pharmaceutical Co., Ltd. a corporation with its nrincioal nlace of business located at One 
Embarcadero Center, Suite 2020, San Francisco, CA. 94111. 
The Pfizer Defendants 
26. Defendant Pfizer, Inc. ("Pfizer") is a Delaware corporation with its principal place of 
business located at 235 East 42nd Street, New York, NY 10017. With the merger of Pfizer 
and Pharmacia Corporation in 2003, Pfizer became the largest drug company in the world 
today. 
27. Defendant Pharmacia Corporation ("Pharmacia") is a Delaware corporation with its 
principal place of business located at 235 East 42nd Street, New York, NY 10017-5755. , 
28. Defendant Pharmacia & Upjohn Company Corporation ("P & U"), a subsidiary of 
Pharmacia Coiporation, is a Delaware corporation with its principal place of business 
located at 235 E. 42nd Street, New York, NY 10017-5703. 
29. Defendant G.D. Searle, L.L.C. ("Searle"), a subsidiary of Pharmacia Corporation, is a 
Delaware limited liability company with its principal place of business located at 4901 
Searle Parkway, Skokie, IL 60077-2919. 
30. Defendant Agouron Pharmaceuticals, Inc. ("Agouron") is a California coiporation with its 
principal place of business located at 10777 Science Center Drive, San Diego, CA 92121, 
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31. Pfizer, Pharmacia, P & U, Searle and Agouron (collectively the "Pfizer Defendants") are 
diversified healthcare companies that individually, and/or [n combination with one 
another, engage in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agencies nationwide. 
Defendant Qualitest 
32. Defendant Qualitest Pharmaceuticals, Inc. ("Qualitest") isj an Alabama corporation with its 
principal place of business located at 130 Vintage Drive 2JIE, Huntsville, AL 35811. 
Defendant Schwarz 
33. Defendant Schwarz Pharma USA Holdings, Inc. ("Schwa|rz") is a Delaware corporation 
with its principal place of business located at 103 Foulk Kd Suite 202, Wilmington, DE 
19803. Schwarz is a wholly-owned U.S. subsidiary of Schwarz Pharma AG, a German 
coiporation with its principal place of business located at| Alfred-Nobel-StraBe, 10 
Monheim, Germany. 
Defendant Taro 
34. Defendant Taro Pharmaceuticals USA, Inc. ("Taro"), a >jtew York corporation with its 
principal place of business located at 3 Skyline Drive, Hawthorne, NY 10532. 
Defendant Upsher-Smith 
35. Defendant Upsher-Smith, Inc. ("Upsker-Smith") is a Minnesota corporation with its 
principal place of business located at 13700 1st Ave, N, Minneapolis, MN 55441. 
9 
The Schering Defendants 
36. Defendant Schering-Plough Corporation ("Schering-Plough") is a New Jersey corporation 
with its principal place of business located at 2000 Galloping Hill Road, Kenilworth, NJ 
07033. 
37. Defendant Wamck Pharmaceuticals Corporation ("Warrick"), a wholly-owned subsidiary 
of Schering-Plough, is a Delaware corporation with its principal place of business located 
at 12125 Moya Blvd., Reno, NV 89506-2600. 
The Wveth Defendants 
38. Defendant Wyeth, Inc. ("Wyeth"), formerly American Home Products Corp., is a 
Delaware corporation with its principal place of business located at Five Giralda Farms, 
Madison, NJ 07940. 
39. Defendant Wyeth Pharmaceuticals, Inc. ("Wyeth Pharm"), a division of Wyeth, is a 
Delaware corporation with its principal place of business located at 500 Areola Road, 
Collegeville, PA 19426. 
NATURE OF THE CASE 
40. This is a civil action for damages and civil penalties pursuant to the Utah False Claims 





The Utah Medicaid Program 
41. Utah Medicaid is a state-administered program with federal matching funds that pays for 
medical care, including prescription drug benefits, for Utah's low-income and disabled 
citizens. Utah Medicaid currently covers about 300,000 individuals. Prescription drug 
benefits represent about 14% of Utah Medicaid's annual qost of approximately SI.5 
billion. The prescription drug benefit cost has increased dramatically in recent years from 
$47.5 million in 1996 to $207.6 million in 2005, an increase of 437% in nine years or a 
compounded rate of 17.8% per year. 
42. Utah Medicaid reimburses medical providers, including pharmacies and physicians, 
pursuant to statutoiy and administrative guidelines and formulae for drugs prescribed for, 
and dispensed or administered to, Utah Medicaid recipients. 
43. Reimbursement amounts for prescription drugs under Utah Medicaid are based on pricing 
information supplied by Defendants to industry reporting services. This information 
includes the following price indices: (I) Average Wholesale Price ("AWP"). which is 
commonly understood as the average price charged by wholesalers to retailers, such as 
hospitals, doctors and pharmacies, for prescription drugs, (ii) Wholesale Acquisition Cost 
("WAC"), which is commonly understood as the average price paid by wholesalers to the 
manufacturers for prescription drugs, and (iii) on occasion (but prior to 2003), Direct 
Price, which is commonly understood as the price chars-ed by drug manufacturers to non-
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wholesaler customers for prescription drugs. At all times relevant to this action, 
Defendants were aware of Utah Medicaid's drug reimbursement guidelines, formulae and 
procedures for prescription drugs. 
The Defendants' Reporting of Inflated Pricing Information 
44. Defendants knowingly, willfully, wantonly, and/or intentionally provided, or caused to be 
provided, false and inflated AWP, WAC, and/or Direct Price information for their 
respective drugs to various nationally known drug industry reporting services, including 
First DataBank (a/k/a Blue Book), Medical Economics, Inc. (a/k/a Red Book), and 
Medispan. These reporting services provide the pricing information to various third party 
payers, such as Utah Medicaid, who have contracted to receive the pricing data as a basis 
to determine reimbursement amounts to the providers who dispense or administer the 
drugs to Utah Medicaid patients. Given the tens of thousands of separate National Drug 
Codes ("NDCs") and the hundreds of thousands of prescription drug claims electronically 
filed each month with Utah Medicaid, the State has no other feasible alternative to relying 
on these drug industry reporting services. The State quite literally relies on the honesty 
and fair dealing of the phannaceutical manufacturers in reporting their pricing information 
to these drug industry reporting services, Pharmaceutical manufacturers are keenly aware 
of this reliance and some, including the Defendants, have chosen to exploit it to their 
benefit and the detriment of taxpayer-funded Medicaid. 
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45, Utah Medicaid purchased and utilized the Defendants1 published AWP, WAC, and/or 
and Medical Economics, Inc. 
used by Utah Medicaid with 
At all relevant times to this 
Direct Price information from First DataBank (Blue Book], 
(Red Book). The information from Blue Book was and is | 
respect to reimbursement for pharmacy-dispensed drugs. 
action, Utah Medicaid relied upon the AWP, WAC, and/ot Direct Price provided by 
Defendants to the industry reporting services in determining the amount Utah Medicaid 
reimburses providers. 
46. Defendants knew that the false and deceptive inflation of (AWP, WAC, and/or Direct Price 
for their drugs would cause Utah Medicaid to pay excessive amounts for these drugs. 
Defendants' inflated AWPs, WACs, and Direct Prices greatly exceeded the actual prices at 
which they sold their drugs to retailers (physicians, hospitals, and pharmacies) and 
wholesalers. Defendants' reported AWPs, WACs, and/or. 
misleading and bore no relation to any price, much less ar 
A few representative examples are listed in the attached pxhibit A. 
47. Defendants knowingly, willfully, wantonly, and/or intentionally concealed the true AWP, 
WAC, and/or Direct Price information for their respective drugs from Utah Medicaid. 
Direct Prices were false and 
wholesale or actual sales price. 
Price which it reports to the 
including Utah Medicaid and 
Each Defendant knows its own AWP, WAC, and Direct [ 
industry reporting services for use by third party payers, 
other state Medicaid programs. Each Defendant also knbws whether the prices it reports 
to the reporting sendees accurately and truthfully represent the actual prices as reflected 
13 
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by market experience and conditions. Unless governmental or industry surveys, lawsuits, 
or criminal or regulatory investigations publicly reveal the true AW?, WAC, or Direct 
Price for a particular drug at issue, Utah Medicaid, like other state Medicaid programs, is 
not privy to the actual market prices which can then be compared to the reported prices. 
Defendants have concealed true market pricing information from the State for the purpose 
of avoiding detection of the fraudulent scheme described herein. 
Defendants used undisclosed discounts, rebates, charge-backs and other inducements 
which had the effect of lowering the actual wholesale or sales prices charged to their 
customers as compared to the reported prices. In addition, Defendants employed secret 
agreements to conceal the lowest prices charged for their pharmaceutical products. As a 
result of these concealed inducements and agreements, Defendants have prevented third 
parties, including Utah Medicaid, from determining the true prices it charges its 
customers. 
Defendants' Marketing of the "Spread" 
Defendants refer to the difference between the reported AWP and WAC, on the one hand, 
and the actual price of a drug, on the other, as the "spread" or, alternatively, "return to 
practice" or "return on investment." Defendants knowingly and intentionally created a 
"spread" on their drugs and used the "spread" to increase their sales and market share of 
their drugs, thereby increasing their profits. Defendants induced physicians and 
pharmacies to purchase their drugs, rather than a competitor's drugs, by persuading them 
14 
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that the larger "spread" on Defendants' drugs would allow 
money, and thereby make more of a profit, through higher 
of Utah Medicaid. 
me providers to receive more 
reimbursement at the expense 
50. Defendants manipulated and controlled the size of the "spread" on their respective drugs 
by both increasing their reported AWPs, WACS, and Direct Prices and decreasing their 
actual prices to wholesalers and providers over time. 
51. In addition to manipulating the reported AWP, WAC, and/or Direct Price. Defendants 
used free goods, educational grants and other incentives tcb induce providers to purchase 
their drugs, all of which lowered the actual prices of the Defendants' drags, resulting in 
increased profits for providers, as well as increased market share and profits for the 
Defendants, at the expense of Utah Medicaid. 
52. The unfair, fraudulent, wanton, and deceptive practices engaged in by the Defendants in 
creating and reporting, or causing to be reported, false and inflated AWP, WAC, and/or 
Direct Price information for their drugs, or otherwise concealing actual pricing 
information, and marketing the "spread" on their drugs as an inducement to providers to 
utilize Defendants' drugs, has resulted in the State paying tens of millions of dollars in 
excess Medicaid payments, while at the same time enricping Defendants with excessive, 
unjust and illegal profits primarily from the resulting increased sales of then drugs. 
53. Drug manufacturers are aware of the AWPs reported by their competitors and of the 
actual sales prices of their competitors' products. Drug Manufacturers manipulate their 
15 
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own AWPs in order to gain or maintain a competitive advantage in the market for their 
products. 
Some of the conduct described herein goes back over 10 years prior to the filing of the 
original complaint in this action. As explained above, however, the nature and extent of 
the fraudulent scheme were not known to the State because information concerning the 
true prices which should have been reported to the reporting services was concealed and 
not publicly available, It has only been through recent regulatory investigations, criminal 
actions, and civil actions that the impact of the fraudulent scheme on the State has been 
indicated or revealed. Even today, the true market prices for many of the drugs in question 
for the entire time period at issue are not known by the State. 
Additionally, it would be impractical, if not impossible, to list in this Complaint, for the 
entire time period that the inflated pricing scheme has been in effect, the true market price 
as compared to the reported price for each NDC in question. It is not unusual for a drug 
manufacturer to report fluctuating prices for a particular drug on multiple occasions within 
a particular year, month, week, or even day. To display pricing reports for all of the 
Defendants and all of the NDCs in question over a ten-year-plus period would be a 
massive undertaking. Limitations of time and space do not permit that information, even 
if it were aivailable, to be set forth in this pleading; however, some representative 






For purposes of specificity of pleading, particularly with rispect to the fraud allegations, 
suffice it to say that Defendants are and have been on notice of the claims asserted herein 
as a result of the many investigations and actions undertaken around the country on this 
same subject. Indeed, each Defendant should know without further allegation from the 
State exactly how its reported prices compare to its true prices and whether it has engaged 
in an inflated pricing scheme regarding prescription drugs. 
FIRST CLAIM FOR RELIEF 
(Restitution, Costs and Civil Penalties under the Utah False Claims Act) 
59. 
Plaintiff incorporates paragraphs 1 through 56 as if fully ?et forth herein, and further 
alleges as follows: 
Defendants violated the Utah False Claims Act as codifidd in the Utah Health Code at 
Title 26, Chapter 20 of the Utah Code Annotated. Defendants issued false and inflated 
AWP, WAC, and/or Direct Price information for publication by the industry reporting 
sendees, in violation of Utah Code Annotated §§ 26-20-3 and 26-20-7. Because of 
Defendants' fraudulent conduct and misrepresentations, Utah Medicaid relied on the false 
information in setting prescription drug reimbursement rates. Defendants "knowingly" 
acted in deliberate ignorance or reckless disregard of the truth, and in so doing, caused the 
State to pay false claims due to the grossly excessive reimbursements for Defendants' 
prescription drugs. 
Under Utah Code Annotated § 26-20-9.5, Defendant is liable for the following damages: 
17 
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a. Full and complete restitution to the state of all damages that the State sustained; 
b. The costs of enforcement, including but not limited to the cost of investigators and 
attorneys; 
c. A civil penalty equal to three times the restitution amount; and 
d. A civil penalty of $5,000 to $105000 for each false claim filed. 
6U. These costs and penalties are in addition to and not a substitute for other damages caused 
by Defendants' actions. 
SECOND CLAIM FOR RELIEF 
(Common Law Fraudulent Misrepresentation) 
61. Plaintiff incorporates paragraphs 1 through 60 as if fully set forth herein, and further 
alleges as follows: 
62. Defendants committed fraud against the State and its single state agency administering 
Utah Medicaid, the Utah Department of Health. Defendants reported or caused to be 
reported AWP, WAC, and/or Direct Price for their respective products on a periodic and 
continuing basis for publication and dissemination to third party paj'ers, including Utah 
Medicaid and other state Medicaid programs. Defendants knew that the AWP, WAC, 
and/or Direct Price information that they provided and caused to be reported was false and 
material to the determination of Utah Medicaid reimbursement rates. 
63. Defendants misrepresented the pricing information with the intent of inducing Utah 
Medicaid to rely on the false information in setting prescription drug reimbursement rates. 
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ation for publication by the 
64. Utah Medicaid reasonably relied on the false pricing data in setting prescription drug 
reimbursement rates and making payment based on said rites. Defendants' 
misrepresentations are continuing, as they regularly and periodically continue to issue 
false and inflated AWP, WAC, and/or Direct Price informs 
industry reporting services. 
65. As a result of Defendants' fraudulent conduct, the State his been damaged by paying 
grossly excessive amounts for Defendants' prescription drugs. 
66. By engaging in the acts and practices described above, the Defendants have engaged and 
continue to engage in repeated fraudulent acts and practices in violation of Utah common 
law. 
67. Defendants' conduct was and is knowing, intentional, grolss, oppressive, malicious, 
wanton, and/or committed with the intention to cause injury. These actions subject 
Defendants to an award of punitive damages sufficient to punish the Defendants and make 
an example of them. 
JURY DEMAND 
The State respectfully requests a trial by jury pursuant to [Rule 38, Utah R. Civ. Proc. 
PRAYER FOR RELIEF 
Wherefore, Plaintiff, the State of Utah, prays for relief ad follows: 
1. For the costs of enforcement pursuant to § 26-20-9.5(2)(p), Utah Code Ann.; 
2. For an award of full and complete restitution to the State 
proved at trial; 
19 
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3. For punitive damages for the wanton and reckless conduct as outlmed herein and 
as an example for the benefit of all other drug manufacturers that wrongly 
misrepresent the prices of their products to the detriment of Utah Medicaid; 
4. For civil penalties pursuant to § 26-20-9.5(2)(c), Utah Code Ann., equal to: 
a. Three times the restitution amount; and 
b. $5,000 to $10,000 for each false claim filed with Utah Medicaid. 
5. For an award of costs and prejudgment interest; and 
6. For such other and further relief as may be justified and which Plaintiff may be entitled to 
by law including, but not limited to, all court costs, witness fees and deposition fees. 
Respectfully SUBMITTED and DATED this p day of June, 2008. 
MARKL.SHURTLEFF 
Attorney General of Utah 
RAYMOND A. HINTZE 
Chief Deputy Attorney General 
ROBERT STEED 
Assistant Attorney General 
Director, Medicaid Fraud Control Unit 
DAVID R. STALLARD 
Assistant Attorney General 




KENNETH D. LOUGEE 
W. DANIEL "DEE" MILES, III 
•CLINTON C. CARTER 
JOSEPH W. STEELE 
Special Assistant Attorneys General 
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CERTIFICATE OF SERVICE 
I hereby certify that on the 10 day of June, 2008,1 served the attached 
documents (Amended Complaint and Jury Demand, and Notice of Amendment) by mail 
on the following: 
Mr. Matthew Solum 
msolum@ldrkland.com 
KJRKLAND & ELLIS 
Citigroup Center 
153 East 53rd Street 
New York, NY 10022 
Attorneys for Oualitest Pharmaceuticals, Inc. 
Mr. George M. Haley 
Mr. David Parkinson 
george.haley@hro.com; david.parkinson@hro.com 
HOLME ROBERTS & OWEN 
299 South Main Street, Suite 1800 
Salt Lake City, UT 84111 
Attorneys for Pfizer, Inc. 
Mr. David G. Greene 
dgreene@lockelord.com 
LOCKE LORD BISSELL & LIDDELL LLP 
885 Third Avenue, 28th Floor 
New York, NY 10022 






Through the following list, the State of Utah intends to capture not only the drug names 
listed, but also all variations of the drug names which incorporate prefixes, suffixes, modifiers, 







































































































































































































































PR LOSEC 1 
PR MAXIN 1 
PR NIVIL 













SODIUM CHL 1 














VANCOCIN ~ 1 
VANCOMYCIN 1 




















































CODEINE 15 | 
CODEINE PH | 
CODEINE SU 
COMBIPRES I 
































































































































SODIUM POLY SULFONATE 
[SODIUM CHLORIDE 
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VALPROIC A 1 









































































































DESENEX AF 1 
DESFERAL 
DEXACIDIN 1 































































































































































































































































































































































QUINAPRIL ~ 1 
QUINIDINE | 
QUININE SU I 
RELPAX 









SODIUM CHL 1 
SOLU-CORTE 
SOLU-MEDRO \ 
SPIRONOLAC ~ 1 




































































ATROPINE S 1 
BACLOFEN "1 
BENZONATAT j 



























































































































































































































































































































ETRAFON I 1 






FULVICIN P 1 
GARAMYCIN 1 
GLYBURIDE 1 

























NOXAFIL PO 1 
OPTIMINE 








POTASSIUM ~ 1 
PROVENTIL 1 
REBETOL 






















































































































































































































































































































































































































































































932 P2d o22 309 Uuah Kc\ Rep 5 Criminal 
Lav, o 1136 
Plainuffs failure to oDiect to irrigation COTI 
pan's s assertion of Limitation of Landovnei 
Liabilm Act as aefense m motion for luagmem 
on pleadings on grounds that compam failea to 
laise defense ID answer -waived compam s de 
fective mode of placing Act in issue U C A 
1953 57-14-6 Rules Cn Proc Rules S^ b c e) 
12(b) (b)(6) (hj Goldmg \ Ashto Cent Irr 
Co P90 793 P 2d 897 Appeal And Erroi C=> 
196 
Defendant m negligence action waived issue 
of mitigation of damages fy failing to raise the 
issue as an affirmative defense in his answer to 
complaint or present eudence or argument on 
mitigation at trial P^ules Ci\ Proc Rules 8(c) 
J 2(h) 15(b) Gill \ Timm 1986 "20 P 2d 
1352 Appeal And Error o=> 173(2) 
Defense of election of remedies is an affirma 
tive one and must be raised h\ wa\ of answei 
notion or demana so as to put issue before 
RUIJES OF CIVIL PROCEDURE 
trial counj and is not to be raiseo for first time 
on appeal the aefense ma's be waived or a 
litigant m ^ be estopped to assert such aefense 
Rules of Uivil Proceduie rules 8(b c) 12(a-c) 
Rcr\al Resources Inc > Gib^altei Financial 
Corp 197Q o03 P 2d 793 Appeal And Error 
o 173(2) Election Of Remedies C=> 1 Election 
Of Remedies c=> 1 o 
In considering motion to dismiss complaint 
Doth distr cl court and Supreme Court on re-
view are Jo s u n ^ its allegations m light most 
favoiable to plaintiff and grant dismissal onh if 
plaintiff could not lr an} event establish a right 
to recover Barrus -^  Wilkinson 1965 16 "Utah 
2d 20* 398 P 2d 207 Appeal And Error c=» 
919 Pleading c=> 3^(3) Pleading o=> 354 Pre 
trial Procedure c=> 622 
A point pa's not be raised for the first time on 
appeal Rules of Civil Proceaure rules 8(cj, 
12(h) Tvgesen ,\ iviagna Water Co 1962 13 
Utah 2d 3|97 375 P 2d *56 Appeal And Error 
c=> 169 
RULE 9. PLEADING SPECIAL MATTERS 
(a)(1) Capacity. It is not necessarv to aver thfe capacin of a parfr to sue or 
be sued or the authority of a part} to sue or be sued m a representative capacity 
or the legal existence of an organized association of persons that is made a 
party A part} may raise an issue as to the legal existence of an} party or the 
capacity of any part}' to sue or be sued or the authority of a party to sue or be 
sued m a representative capacity by specific negative averment, which shall 
include facts withm the pleader's knowledge If raised as an issue, the party 
relying on such capacity, authority, or legal existence, shall establish the same 
on the trial 
(a)(2) Designation of unknown defendant When a party does not know the 
name of an adverse party, he may state that fact m the pleadings and 
thereupon such adverse party may be designated m any pleading or proceeding 
b} am name, provided, that when the true nkmc of such adverse party' is 
ascertained, the pleading or proceeding must be amended accordingly 
(a)(3) Actions to quiet title, desenpnon of interest of unknown parties In an 
action to quiet title wherein anv of the parties are designated in the caption as 
unknown ' the pleadings ma^ describe such unknown persons as ' all other 
persons unknown claiming any right, tide, estate or interest m, or hen upon 
the real property described m the pieacLng adverse to the complainant's 
ownership, or clouding his title thereto 
(b) Fraud, mistake, condition of the mind. In all averments of frauc or 
mistake, the circumstances constituting fraud or mistake shall be stated \\ith 
particulars Malice, intent, knowledge and other condition of mind of a 
person ma^ be averred generally 
(c) Conditions precedent In pleading the performance oi occurrence of 
conditions precedent, it is sufficient to a^er generalK that all conditions 
precedent ha\e been performed oi ha\e occurrp.h A rU-iial of perfoimance oi 
A0077 
PLEADINGS, MOTIONS & ORDERS Rule 9 
occurrence shall be made specifically and with particularity, and when so made 
the party pleading the performance 01 occurrence shall on the tnal establish 
the facts show mg such performance or occurrence 
(d) Official document or aci In pleading an official document or act it is 
sufficient to aver that the document was issued or the act done in compliance 
with law 
(e) Judgment. In pleading 2 judgment or decision of a domestic or foreign 
court, judicial or quasi judicial tribunal or of a board or officer it is sufficient 
to aver the judgment or decision without setting forth matter showing jurisdic-
tion to lendei it A denial of jurisdiction shall be made specifically and with 
particularity and when so made the parts pleading the judgment or decision 
shall establish on the trial all controverted jurisdictional facts 
(f) Time and place. For the purpose of testing the sufficiency of a pleading, 
averments of time and place are material and shall be considered like all other 
averments of material matter 
(g) Special damage. When items of special damage are claimed, they shall 
be specifically stated 
(h) Statute of limitations. In pleading the statute of limitations it is not 
necessary to state the facts showing the defense but it may be alleged generally 
that the cause of action is barred by the provisions of the statute relied on 
referring to or describing such statute specifically and definitely by section 
number, subsection designation, if any, or otherwise designating the provision 
relied upon sufficiently clearly to identify it If such allegation is controverted, 
the party pleading the statute must establish, on the trial, the facts showing that 
the cause of action is so barred 
(1) Private statutes; ordinances. In pleading a private statute of this state, or 
an ordinance of any political subdivision thereof, or a right derived from such 
statute or ordinance, it is sufficient to refer to such statute or ordinance b} its 
title and the day of its passage or by its section number or other designation m 
any official publication of the statutes or ordinances The court shall there-
upon take judicial notice thereof 
(j) Libel and slander. 
(jXl) Pieaaing defamaton moitei It is not necessary m an action foi libel or 
slander to set forth any intrinsic facts showing the application to the plaintiff of 
the defamatorv matter out of which the action arose, but it is sufficient to state 
generally that the same was published or spoken concerning the plaintiff If 
such allegation is controverted, the party alleging such defamaton matter must 
establish, on the trial, that it was so published or spoken 
(j)(2) Pleading defense In his answer to an action for libel or slandei, the 
defendant may allege both the truth of the matter charged as defamaton? and 
any mitigating circumstances to 1 educe the amount of damages, and, whether 




Rule 9 ]RULES OF dVIL PROCEDURE 
(k) Renev* judgment A complaint alleging failure to pay a judgment shall 
describe the judgment with particular^} or ajtach a copy of the judgment to the 
complaint 
(/) Allocation of fault. 
(Z)(l) A party seeking to allocate fault [to a non-part} under Title 78B, 
Chapter 5, Part 8 shall file 
(I )(l)(A) a description of the factual and 
allocated, and 
(/)(1)(B) information known or reasonably available to the party identifying 
the non-party, including name, address, telephone number and employer If 
the identity of the non-party is unknown, the 
(/ )(2) The information specified m subsecc 
party's responsive pleading if then known on : 
legal basis on which fault can be 
part} shall so state 
jtion (/ )(1) must be included m the 
must be included m a supplemen-
tal notice filed within a reasonable time afier the party discovers the factual 
and legal basis on which fault can be allocated but no later than the deadline 
specified m the discovery plan under Rule 26(f) The court, upon motion and 
for good cause shown, may permit a party to file the information specified m 
subsection (/ )(i) after the expiration of any period permitted b} this rule, but m 
no event later than 90 days before trial 
(/ )(3) A party ma} not seek to allocate fauj.lt to another except by compliance 
with this rule 
[Amended effective November 1, 2003, May 2,20105, November 1 2008] 
Cross References 
Joinder of defendants allocation of fault to non-parrv 
which fault can be allocated and information 
description of factual and legal basis on 
identifying non-party, sec § 78B-5-821 
Library References 
Damages C=>142 
Limitation of Actions O l ^ b to 192 
Pleading ^ 4 6 18 59 
Vvestlavv Ke\ Number Starches 302k4b 
302U8 302L59 U5kM2, 24JL376 to 
241L192 
Research References 
|J S Damages §§ 225 to 228 
J S Limitations of Actions §§ 269 to 285 
287 to 290 
J S Pleading §§ 70 to 73 96 136 to 138 
lo2 lo5 
Forms 
Am Jur PI & Pr Foims Laboj and Laboi 
Relations § 3 Procedural Rules Reieiences 
Standing, 
Challenging constitutionality ol legisla-
tion see Diamond \ Cha/les U S 111 
198o 106 SCt lo97 47o U S 54 Q0 
L Ed 2d 48 
Federal antitrust action necessity of 
proving injun see Cargill Inc v Mon-
Umted Stales Supreme Court 
fort ot Colorado Inc U S Colo 198o 
107 SCt 464 4"9 US 104 93 
L Ed 2d 427 
Inmn in fact, qui tarn suit bi ought b\ 
individual under False Claims Act, state 
not subicct to Labi lit} m federal court 
Eleventh Amendment immunity see 





IN THE DISTRICT COURT 0? THE THIRD JUDICIAL DISTRICT 
IN AND FOR SALT LAKE COUNTY, STATE (pF UTAH 
STATE OF UTAH, 
Plaintiff, 
vs , 
APOTEX CORPORATION; BAXTER : 
HEALTHCARE CORPORATION; 30EHRINGER 
INGELHSIM CORPORATION; KALLINCKRODT: 
INC.; CSL 3EHRING; FOREST 
LABORATORIES, INC.; MORTON GROVE : 
PHARMACEUTICALS, INC.; MUTUAL 
PHARMACEUTICAL COMPANY, INC.; : 
NOVARTIS PHARMACEUTICALS 
CORPORATION; OTSUKA AMERICA, INC.; : 
PFIZER, INC.; QUALITEST 
PHARMACEUTICALS, INC.; SCHSRING- : 
PLOUGH CORPORATION; SCHWARZ PHARMA 
USA HOLDINGS, INC.; TARO : 
PHARMACEUTICALS USA, INC.; UPSEER-
SMITH, INC.; andWTETH, INC., : 
Defendants. : 
MEMORAJNDUM DECISION 
CASE N|O. 080907678 
This matter came before the Court 
2005, in connection with defendant Pfizer, Inc 
Dismiss the Amended Complaint. The Court notes 
remain oineci m >&-r ' q M r . H 
xr inq on December 
^ i i C iLiCL ; U I JL r^,y - T V p" 
•¥'-'• 
STATE V. APCTEX COR?. PAGE 2 MEMORANDUM DECISION 
to their.1 At the conclusion of the hearing, trie Court: cook the matter 
under advisement to firtr.er consider the parties' written submissions, 
the relevant legal authority and counsel's oral argument. Being now 
fully informed, the Court rules as stated herein. 
LEGAL ANALYSIS 
At the outset, the Court notes tnat Pfizer's Motion to Dismiss is 
brought pursuant to both Rule 9(b) and Rule 12 (5) (6) of the Utah Rules 
of Civil Procedure and seeks dismissal of the State of Utah's (tne 
"State") Amended Complaint. The Amended Complaint alleges that the 
defendant pnarmaceucicai companies committed fraud m connection with the 
pricing of prescription drugs. Specifically, tne defendants are alleged 
to nave knowingly and falsely inflated pricing information, which the 
State tnen relied on m determining reimbursement rates under its 
Medicaid program. The State's first claim for relief alleges that 
n
 [d] efendants issued false and inflated AKP, KAC and/or Direct Price 
information2 for oublicaticn bv the mdistrv reocrtmo services . . " m 
violation of tne Utah Fslse Claims Act Utan Code Ann. § 25-22-1 et. 
3
 Defendants films supplemental memoranda include Defendant Boehrmger Ingelheim 
Corporation ("BIC"). defendants Mallinckrodt, Inc and Taro Pharmaceuticals USA. Lie 
(/'Generic Defendants*"] and defendant Morton Grcn e Pharmaceuticals. Inc ("Morton Gro\ e"). 
:
 In discussing the pricing information* the parties ha"\ e used a number of acronyms 
Since these acronyms are commonh understood and used b\ the panes, the Court will not define 
then herein 
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c c^rr^nr premised or. fraudulen 
-isrepresentamcn. 
In its tone:., Pfizer first argues thai: wh^ 
oased clairr and its False Claims Act claim reauire corrYDLiar.ee v,-tm Rule 
9 (n) 
-c^ e ..as za-it leaa mese c_aim£ wii!: parcicuLancv. 
Pfizer complains mat me Amended CompLair.t doe| 
individual defendants' alleged misconduct, does not 
defendant reverted \\nicn false and inflated prices 
v*maft defendant: provided such allegedly inflated pricing information to 
le m e State' 
s not oelmeate earn 
elaborate as to whim 
and does not identify 
me "iDQvszry reporting services." Pfizer also 
Amended Complaint fails to identify when and 
misstatements *ere made. 
Pfizer has cited a number of cases v;him idert 
for pleading fram wich particularity These $ 
plaintiff ~ust plead :^:r. specificity tne reLevafc 
sum as tne ti^e, place and contents, of false : 
- V 
:e terser, marina m e misrecr 
woros, tne party must t* 
how" of me alleged fra 
Furthermore, *he: 
points out that the 
t o \Cion 
~. i zv t n e v-or" * - v-ciT-i^ .-r- — ^ 
;.:sc2> - : : u ^ c a t e 
s ~r r e n a m e 
a i w c 
s w _ v t S 
^t^^CX— Ci _ ~ . 
W . . S > ^ZLK , 5 4 i 
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422, 424 'D. Utah 19S6) (indicating that Rule 9(b) particularity 
requirements are ''especially important m cases involving multiple 
defendants"). 
zer mas a Iso cited a number of cases which apply tnis heightened 
pleading stancara m tne specnic context or utigaticn involving claims 
cf pharmaceuticals overstating prescription drug prices. It appears that 
these cases are typically brought oy states and private insurers who 
reimburse and patients wr.o have made coinsurance payments, all based on 
published AK?'s, wmch are alleged to be false and inflated. These cases 
are particularly instructive because they identify how shortcomings m 
pleading witn particularity can oe re-pled to provide greater specificity 
cf allegations m order to meet Rule 9(b) recuirements. 
Nctanlv, the State nas tacitlv acknowledoed its failure to dead 
witn particularity. Tr.e State's reasoning for not dcmg so is that the 
'"K v-s'l
 & ; 
:&~c c_c_7ib *. • c ^ p c ^ ~ -
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The Court is similarly unoersuacea DV tne Stat$' s aroument that 
maarcs . Court car. simply relax the Rule 9 (b) 
Tenth Circuit case law specifically declining :o r 
of Rule 9'r>) and instead indicating that u]d]ef 
obligation :c research missing information for 
Rather, plaintiff must plead [its] claim Vvith suf 
:hat lie defendants are on notice of which specifi^ claims are alleqedly 
false." U.S. ex rel. Sikkenca v. Reoence Blueshield of Utah, 2001 U.S 
rst, Pfizer has cited 
elax tne requirements 
fendants are under no 
each specific claim. 
ficient oarticularitv 
Lexis 25717 ;D. Utah Nov. 27, 2001). 
Further, the Court is not convinced that the State is unable to 
obtain essential information regarding the defendants' pricing methods, 
such that relaxing the Rule 9(b) standard is warranted. Indeed, Exhibit 
A to the State's Amended Complaint, w.tich contains a list with va few 
es" of the soectf ic m s , c t : s c . . L C u - \ c c A i i 
I ~ e r e : » - U i Oil 
a •_• ^ ~ a — i . c »-
;_ci5 w. - a. c c s : 
r>--e;%^- ' 
• s. rv 
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individual defendant for which they provided an allegedly fraudulent or 
false price. Zhe nroadly-worded, blanker: allegations of fra^d m the 
Amended Complaint against the defendants as a collective will not suffice 
-r.der Rile 9 (h) 
However, rather tnan dismissing the State's Amended Complaint, the 
Court grants tee State leave to amend m order to (1) identify the 
specific drug at issue; (2) identify the specific defendant involved m 
that drug's sale, manufacture or for which they provide prices for; (3) 
the allegedly false publication of that specific drug's pricing, to whom 
that publication was made and when; and (4) whether the State actually 
used or relied on the allegedly false pricing information which was 
reported m setting reimbursement rates. To the extent possible, the 
State should also identify the actual price that snould have reen 
puclisited and identity of the party p^rcnasmg tne drug. 
Further, with respect to allegations that the defendants engaged m 
a practice wnich nas Deer, termed as a "marketing of tne spread" between 
AVC? and KAC, tne State rn^st also identify n, the specific defendant 
engaging m this practice- (2) specifics of now providers 'were induced 
to purchase the specific drug i e. prevision of free goods, educational 
grants and other incentives and 2, the actual zs.rcha.se price of tne 
drug to the pharmacy and/or pnysician. 
Kicn respect to tne State's claim under tne False Claims Act, a 
fundamental element is tne s~uo~issicn of a clai~ fcr a medical nenefit 
t>l ^ ~ 7 KEM0?A1\DUK DECISION 
the State' s Amended CoTjlair.: does nor allege wiu.v 
of the defendants submtted claims to the State <p 
submt claims. Furtner, it remains unclear vtiat b 
derived directly from the State, ratner tnan from 
urucs nv tnysicians and or.armacies . Ti 
specimen i.y tnat any 
:r directed others to 
^nefit the defendants 
:he tarcr.ase of tneir 
enament snoula aocress 
:ese snortc W l ~.Z> . 
witn respect to 3IC, the State should fodus on this company's 
separate corporate existence and identify only those drugs for which 3IC, 
and not its corporate subsidiaries, is legally responsible. It appears 
m a t three of BIC's subsidiaries are mentioned m the Amended Complaint 
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TPe renaming issje presented py tr.e defendants' Motion is *netne: 
:ne 2007 arrencnents 10 tr.e Utar. False Claims ACT: apply retroactively 
rr.e State presently relies on :r.e 2007 version of tne Act m its reo^est 
-r>y" T-s 
Tr.e sarnies agree tr.at amendments are prospective unless expressly 
race retrcactive py one legislature Tr.e State's position is tnat § 26-
20-15^2 of one Act evidences an intent chat one amendments Pe 
retroactive Section 26-20-15(2) provides that u[al civil action orougnt 
under tnis chapter may pe prougnt for acts occurring prior to the 
effective date of this section if one limitations period set fcrtn in 
Section (1) nas not lapsed " 
Tr.e defendants counter that tr.is retroactivity pro\_sion is located 
r.e amenae <JL s ^a L « U : ooes 
n e t a o o ^ t o t ; . u - . : c * v 1 C O C — £S~ .en cormoare o t n e ] 
:s *n i cn v e r s amenoea ; *r.ere one _egis - .a tw. re e x p r e s s l y maae _ i a m _ i t y 
c ~ c e r "^  i n e d 
eacn or t r .es e Ac 
-U id" 
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the amendment extending the statute of limitation^ period was intended 
to be retroactive. 
To summarize, msteaa or granting 
Dismiss, Court will allow ti State to i 
Complaint consistent with the Court's guidelines, ^ 
State must file its Second Amended Complaint wi 
Memorandum Decision or the Court will enter a di^ 
Complaint en the grounds that the State failed to 
pendants' Motions to 
Le a Second Amended 
: outlined above. The 
.hin 4 5 days of this 
missal of its Amended 
olead its claims with 
sufficient particularity. 
Because the Court will permit the State to amend its Amended 
Complaint, it aoes not reach tr.e issue of wnetner the State's claims 
:d and violation of the raise Claims Act ar^ also susceptible to 
CIST.. ssal under Rule 12 (b- {6) . 
This Memorandum Decision will stand as the Carder of the Court. 
Dated this day of February, 2 009. 
d ! ! /^/sS 
[YEONE E. MEDLEY 
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IN THE DISTRICT COURT OF THE THIRD JUDICIAL DISTRICT 
IN AND FOR SALT LAKE COUNTY, STATE (t>F UTAH 
STATE OF UTAH, 
Plaintiff, J 
vs. : 
APOTEX CORPORATION; BAXTER : 
INTERNATIONAL, INC.; BOEHRINGER 
INGELHEIM CORPORATION; MALLINCKRODT: 
INC.; CSL BEHRING; FOREST 
LABORATORIES, INC.; MORTON GROVE : 
PHARMACEUTICALS, INC.; MUTUAL 
PHARMACEUTICAL COMPANY, INC.; : 
NOVARTIS PHARMACEUTICALS 
CORPORATION; OTSUKA AMERICA, INC.; : 
PFIZER, INC.; QUALITEST 
PHARMACEUTICALS, INC.; SCHERING- : 
PLOUGH CORPORATION; SCHWARZ PHARMA 
USA HOLDINGS, INC.; TARO : 
PHARMACEUTICALS USA, INC.; UPSHER-
SMITH, INC.; and WYETH, INC., : 
Defendants. : 
MEMORANDUM DECISION 
CASE ND. 080907678 
This matter came before the Court for a hearing on December 11, 
2009, in connection with the defendant pharmaceutical companies' second 
round of Motions to Dismiss the State's Second Amended Complaint. The 
Court notes that defendant Pfizer, Inc.'s Motion to Dismiss has been 
joined in by the majority of the defendants (the "Pfizer defendants"). 
Defendant Morton Grove Pharmaceuticals Inc. (^Morton") has filed separate 
Motions to Dismiss. A group of defendants which [include defendants 
A0098 
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Mallmckrodt, Inc., Taro Pharmaceuticals USA, Inc. and Upsher-Smith 
Laboratories, Inc. ("Generic Defendants'7) and defendant Boehringer 
Ingelheim Corporation (UBIC") have also filed separate Supplemental 
Memoranda m support of their positions seeking dismissal. 
At the conclusion of the hearing, the Court took the matter under 
advisement to further consider the parties' respective legal positions 
and written submissions, the relevant legal authority and counsel's oral 
argument. Being now fully informed, the Court rules as stated herein. 
LEGAL ANALYSIS 
The defendants' Motions seek dismissal of the State's Second Amended 
Complaint under Utah Rules of Civil Procedure 9(b) and 12(b)(6). The 
defendants argue that the State has essentially ignored the Court's prior 
Memorandum Decision, dated February 13, 2009, and that its Second Amended 
Complaint contains the same type of pleading deficiencies addressed by 
the Court in that Decision 
According to the defendants, the State's Second Amended Complaint 
once again fails to plead with particularity its claims for common law 
fraudulent misrepresentation and for relief under the Utah False Claims 
Act. In addition, the defendants assert that dismissal is warranted 
under Rule 12 (b) (6) because the Second Amended Complaint does not plead 
uhe necessary elements of the State's claims, including actual fraudulent 
misrepresentations and the submission of false claims under the False 
Claims Act. The defendants point, for example, to the State's failure 
A nnoo 
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Prior to April 30, 
to plead its reliance on the false pricing allegedly supplied to industry 
reporting services in setting reimbursement rates. 
The Pfizer defendants make a separate argument for dismissal under 
Rule 12(b)(6) based on the statute of limitations 
2007, the statute of limitations under the Utah False Claims Act was one 
year. The Act was amended, effective April 30, 2007, to increase the 
statutory limitations period to six years after the violation, or three 
years after discovery, not to exceed ten years aftjer the violation. In 
the prior Decision, the Court ruled that uthe amendment extending the 
statute of limitations period was intended to be retroactive." The 
Pfizer defendants now argue that the logical progression to the Court's 
ruling is that the amended statute of limitations applies only to claims 
that were not already barred under the prior version of the statute. 
Since the initial limitations period was one year, 
reason that .•. all of the State's claims for cont 
occurred on or before April 30, 2006, are time-barred. 
BIC's supplemental brief argues that the State has again lumped it 
with several independent subsidiaries who are not 
defendants in this case. BIC points out that 
the Pfizer defendants 
duct alleged to have 
even named or served 
despite the Court's 
directive to "identify only those drugs for which BIC, and not its 
corporate subsidiaries, is legally responsible," the Second Amended 
Complaint continues to refer to the "Boehringer Defendants" as a 
collective group. 
A0100 
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With respect to the Generic Defendants, they again detail the unique 
reimbursement method that applies to their specific drugs. The prior 
Memorandum Decision ordered the State to identify how the allegedly false 
publication of AWP's for generic drugs altered this method, which drugs 
were reimbursed using a different method and why the State deviated from 
the general method of reimbursement. The Generic Defendants argue that 
the State has failed to provide any of this information, particularly 
with respect to how the typical method of reimbursement was altered or 
influenced by the allegedly inflated AWP's provided by the Generic 
Defendants . 
In Opposition, the State maintains that its Second Amended Complaint 
"vastly exceeds" the notice pleading requirements. The State again takes 
the position that "[t]he Defendants know exactly what is at issue." This 
precise argument was previously rejected by the Court and its Memorandum 
Decision specifically indicated that each of the defendants was entitled 
to know whet they allegedly did wrong. 
The State next asserts that it has now listed the specific drugs at 
issue in Exhibit A to its Second Amended Complaint. However, this list 
also contains drugs that the defendants did not manufacture and products 
that are referenced only by their chemical compounds. Exhibit A also 
identifies non-prescription drugs and broad categories of drugs such as 
*antibiotic" and "antacid." It also references medical conditions such 
as "arthritis" and "prenatal." The Court agrees with the defendants that 
A0101 
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this list is not helpful and falls far short of the applicable pleading 
(identify the specific 
that should have been 
requirements. Indeed, the State was required to 
drug at issue for each defendant, the actual prices! 
published and the identity of the purchaser. Exhibit A does not provide 
this information. 
With respect to group pleading, the State asserts tnat "tne second 
Amended Complaint makes clear that each Defendant stands on the same 
footing in that each Defendant in this case falsely reported and/or 
suppressed the true prices of its drugs over the relevant time period in 
essentially the same manner." The State re-argues that there is nothing 
wrong with attributing conduct to wall defendants" in this type of 
context since they had a uniform practice in reporting allegedly false 
prices. Again, the Court previously rejected this argument and ruled 
that "broadly-worded, blanket allegations of fraud 
defendants as a collective will not suffice under 
The State again asserts that the Court should apply a relaxed 
standard and as to the Utah False Claims Act, the State re-argues its 
prior position that Rule 9(b) has no application to this Act. The Court 
previously rejected this argument and concluded that Rule 9(b) applies 
to the State's claims. Further, the two supplemental cases that the 
State relies on, United States v. McKesson Corp., 2009 WL 3176168 (N.D. 
Miss.), and United States ex rel. Grubbs v. Kannecrinti, 565 F.3d 180 (5th 
.against the 
(Rule 9 (b) 
A0102 
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Cir. 2009) , confirm that claims under the False Claims Act must meet the 
heightened pleading standard of Rule 9(b). 
Overall, the State maintains that the level of pleading required by 
the Court in its Memorandum Decision is tantamount to the presentation 
of evidence. During oral argument, the State's counsel indicated that 
Grubbs was the State's best case in support of its position that a 
plaintiff alleging the submission of false claims need not detail its 
allegations at the pleading stage and may instead provide the surrounding 
information later, at the uproof stage." 
After considering the parties7 respective legal arguments, the Court 
determines that the defendants' Motions to Dismiss are well-taken and 
that the State's Second Amended Complaint must be dismissed with 
prejudice under both Rule 9(b) and Rule 12(b)(6). 
First, the Court rules that the State's Second Amended Complaint 
fails to satisfy the particularity requirements of Rule 9 (b) . The 
Court's prior Memorandum Decision identified in great detail the 
shortcomings of the State's Amended Complaint and specifically 
articulated what was required in order for the State to meet its burden. 
The Court rules that the State did not comply with the Court's directions 
and failed to add the considerable detail required in order to meet this 
burden. 
Once again, the State has failed to identify each defendant's 
allegedly fraudulent misrepresentations and False Claims Act violations 
Anini 
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with particularity; thereby affording the defendants no particularized 
notice of the allegations against them individually. Indeed, the Second 
Amended Complaint merely offers broad conjecture with respect to 
statements and/or claims that were allegedly false 
were made by the defendants as a group. The 
sufficiently identify the individual defendant's misrepresentations, the 
State's reliance and the consequences thereof. 
|or fraudulent and that 
State has failed to 
the State relies on to 
e Memorandum Decision, 
llure to identify the 
defendants point out, 
lyear period for all 
Moreover, the submission of Exhibit A, which 
demonstrate its good faith effort to comply with th 
is far too general to satisfy Rule 9(b) The fa| 
allegedly false publication of each specific drug'd pricing, to whom that 
publication was made and when, renders the Second Amended Complaint 
fatally deficient and unspecific. As the Pfizer 
the State merely identifies the same fifteen 
publications of all prices for all drugs by all defendants. The Court 
is of the opinion that to find that plaintiff's Second Amended Complaint 
satisfies Rule 9(b) would render the particularity requirements of Rule 
9(b) meaningless. 
With respect to the State's False Claims 4 c t claims, the Court 
remains convinced that these claims are subject 
requirements of Rule 9(b) The State's own supplemental cases, Grubbs 
and McKesson, confirm this point Further, the State's interpretation 
of these cases as purportedly providing a relaxed standard at the 
to the particularity 
A0104 
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pleading stage, with proof to follow, is inapposite of the holdings of 
those cases. Indeed, those cases uniformly held that "to plead with 
particularity the circumstances constituting fraud for a False Claims Act 
. . . claim, a relator's complaint, if it cannot allege the details of 
an actually submitted false claim, may nevertheless survive by alleging 
particular details of a scheme to submit false claims paired with 
reliable indicia that lead to a strong inference that claims were 
actually submitted." McKesson, 2009 WL 3176168 at *6; Grubbs, 565 F.3d 
at 190 (Emphasis added). 
In McKesson, the court determined that the government had alleged 
sufficient detail concerning such a scheme. Indeed, the government had 
provided significant detail and specific examples of the defendants 
submitting false records In evaluating the government's claims under 
Rule 12 (b) (6) , the court found these allegations to be sufficient m 
detailing a conspiracy m furtherance of a scheme. 
In Gr\it>bs, Dr Grubbs, a psychiatrist, alleged that his employer and 
other doctors billed Medicare and Medicaid for services not performed. 
The action was brought under the False Claims Act. As with McKesson, the 
distinguishing fact is that the Grubbs case had "simple, concise and 
particular allegations" of fraad, including the particular workings of 
the scheme. The allegations included dates and times of meetings, 
attempts to assist Dr Grubbs m falsifying medical records, specific 
A0105 
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instances of unprovided services, etc. That level of detail and 
particularized allegations of a scheme are lacking in this case, 
rendering Grubbs and McKesson relevant only to the point that Rule 9(b) 
laim is an essential 
applies to a complaint filed under the False Clairrjs Act. 
Based on the foregoing, the Court rules thatl the State has failed 
to satisfy the requirements of Rule 9(b) with respect to its claim under 
the False Claims Act. The defendants make the valid point that the State 
has again failed to allege specific facts indicating that the defendants 
communicated directly with the State, let alone submitted a claim to the 
State. Yet, the actual submission of a false c 
element to any complaint seeking relief under Utaji' s False Claims Act. 
See Utah Code Ann. § 26-20-7 
Further, while the Second Amended Complaint "\jaguely alludes to the 
defendants directing others to submit false claimp, the State does not 
identify these other individuals and their role in 
allegedly false claims. Equally significant is thl 
concerning the benefit which the defendants derived directly from the 
State. The State merely concludes that a benefit must have been derived 
and ''ultimately ended up in the pockets of the defendants." 
To summarize, the Court determines that the Second Amended Complaint 
phrases its allegations in broad, vague language 
the strictures of Rule 9(b). Therefore, the defendants' Motions premised 
on Rule 9(b) are granted. 
A0106 
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As additional grounds for dismissal, the Court grants the Pfizer 
defendants' Motion on statute of limitations grounds. The Court 
specifically adopts the Pfizer defendants' reasoning m ruling that the 
State's claims for conduct alleged to have occurred on or before April 
30, 2006, are indeed time-barred as a matter of law 
The Court also rules that the State's Second Amended Complaint is 
subject to dismissal under Rule 12(b)(6). In this regard, the Court's 
previous analysis concerning the shortcomings of the Second Amended 
Complaint with respect to Rule 9(b) pleading standards apply equally to 
its analysis under Rule 12(b)(6). 
Specifically, not only has the State failed to plead with 
particularity, but has also failed to allege fundamental elements of 
common lav; fraudulent misrepresentation and for relief under the Utah 
False Claims Act Most notable is the State's failure to plead that the 
pricing information supplied by the individual defendants, as opposed to 
the defendants m general, directly affected its reimbursement rates 
While the Second Amended Complaint generally states that Utah Medicaid 
relied on certain pricing information, there are no specific allegations 
explaining the relationship between the individual defendant's alleged 
false repeating of AWPs and the reimbursement formulas relevant to the 
drugs manufactured by that specific defendant 1 Indeed, the State has 
1This is particularly true with respect to the Generic Defendants, where the State has 
essentially admitted that inflated AWPs are primarily relevant with respect to reimbursement of 
A0107 
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simply not pled how the individual defendant's actiions led the State to 
set its reimbursement rates or how it acted in reasonable reliance on the 
pricing information. The State has also failed to allege that it was 
induced to act by the defendants' alleged misrepresentations. 
While the State generally alleges that the AWPs were inflated, its 
inability to plead reasonable reliance may be explained by its public 
acknowledgment in 1999 that it understood that actual acquisition costs 
for generic drugs was 60.1% below AWP and that 
reflect market prices.2 Since the State knew that 
represent actual market averages, it cannot fulfill! 
of its False Claims Act claim, namely that these 
made a false claim and that the State was deceived! 
setting its Medicaid reimbursement formula. 
Likewise, as the Court discussed above, thfe State has failed to 
include specific allegations pertaining to how any defendant submitted 
or caused to be submitted a false claim, a key element of an action under 
AWP does not in fact 
published AWPs did not 
two required elements 
defendants knowingly 
by published AWP's in 
brand name drugs. 
2
 See State of Utah Dep't of Health, Div. Of Health Fin., Medicaid Pharmacy -
Acquisition Cost of Generic Prescription Drug Products (Feb. 1999b (Attached as Exhibit 2 to the 
Generic Defendants' Reply Memorandum). Under Green River Canal Co. v. Thavne, 84 P.3d 
1134, 1145 n. 8 (Utah 2003), the Court may take judicial notice of this document. Further, under 
Alvarez v. Galetka. 933 P.2d 987, 990 n. 6 (Utah 1997), "items attached to pleading, items of 
public record, and items in trial record will not covert 12(b)(6) mqtion to rule 56 motion for 
summary judgment." (Emphasis added). 
A0108 
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the False Claims Act. Further, to establish a claim under the False 
Claims Act, as well as common law fraudulent misrepresentation, the State 
must allege each individual defendant's intent to deceive, which it has 
failed to do. 
Based on the foregoing and on the additional grounds set forth in 
the defendants' moving papers, which are incorporated herein by this 
reference, the Court grants their Motions to Dismiss. Counsel for the 
various groups of defendants are to prepare Orders consistent wiuh this 
Memorandum Decision and Rule 7(f), Utah R. Civ. P., but also containing 
details specific to their respective individual positions, for the 
Court's review and signature. The Court would prefer that counsel meet 
and confer in an effort to submit Orders approved as to form by counsel 
for plaintiff. If those efforts fail, then Rule 7(f) will control. 
Dated this <^-^ day of February, 2010. 
/s/ 
TYRONE E. MEDLEY 
DISTRICT COURT JUDGE 
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MAILING CERTIFICATE 
I hereby certify that I mailed a true and correct copy of the 
foregoing Memorandum Decision, to the following, this £—K-*' day of 
February, 2 010: 
W. Daniel uDee" Miles, III 
Clinton C. Carter 
Special Assistant Attorneys General 
Attorneys for Plaintiff 
272 Commerce Street 
P.O. Box 4160 
Montgomery, Alabama 36103-4160 
Joseph W. Steele 
Kenneth D. Lougee 
David C. Biggs 
Special Assistant Attorneys General 
Attorneys for Plaintiff 
5664 S. Green Street, Suite 300 
Salt Lake City, Utah 84123 
Robert E. Steed 
Assistant Attorney General 
Attorney for Plaintiff 
Utah Medicaid Fraud Control Unit 
5272 College Drive, Suite 200 
Salt Lake City, Utah 84123-2772 
Brian P. Miller 
Derek J. Williams 
Attorneys for Defendant Apotex 
10 Exchange Place, Eleventh Floor 
P.O. Box 45000 
Salt Lake City, Utah 84145-5000 
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S. PRESCRIBED DRUGS 
Prescribed drugs will be reimbursed based on an established pnbduct cost plus a dispensing 
fee. The payment for individual prescriptions cannot exceed the amount billed. The amount 
billed must be the usual and customary charge to the private pay patient. The following 
methodology is used to establish Medicaid payments: 
Except for special category fees, reimbursement will be the I lower of: 
1. The Utah maximum allowable cost (MAC) plus a reasohable 
provider's usual and customary charge (billed charge) 
dispensing fee or the 
o the general public; 
The Utah estimated acquisition cost (EAC) plus a reasonable dispensing fee or the 
provider's usual and customary charge (billed charge) |to the general public. 
Federal "Upper Limit" 
The federal upper limit is the maximum allowable ingredient cosk reimbursement established 
by the Department of Health and Human Services, Health Care 
selected multiple-source drugs. The aggregate cost of product payment for the drugs on the 
federal upper limit list will not exceed the aggregate established 
Administration. 
Financing Administration, for 
by Health Care Financing 
Average Wholesale Price 
The Average Wholesale Price (AWP) is determined for each dnig by the Utah contract with 
American Druggist, Blue Book First Data Bank. They provide a monthly update of drug 
prices for the Reference File. First Data Bank used AWP from Wholesalers in many states 
for determining AWP in specific regions. 
Utah MAC 
Utah MAC is the Maximum Allowable Cost reimbursement established by the Utah 
Department of Health, Division of Health Care Financing, for se 
(generic) drugs not appearing on the federal upper limit list. Th^se drugs are listed in the 
Pharmacy Provider Manual. 
ected multiple-source 
T.N.# 89-02 
Supersedes T.N. # 87-37 
Approval Date 3-14-89 






S. PRESCRIBED DRUGS (Continued) 
Utah EAC 
The Utah Estimated Acquisition Cost (EAC) is currently AWP minus 17 percent. This estimate 
has been established using information provided by a survey conducted by the Utah 
Department of Health. Effective July 1, 2009, the AWP will be AWP minus 15 percent. 
Dispensing Fee 
In setting the basic dispensing fee, the state will give consideration to costs shown on periodic 
operation surveys, in-house studies of dispensing costs, national and regional data, and 
economic trends and conditions. The Utah base dispensing fee is $3.90. 
Special Category Fees 
1. Payment for insulin, birth control pills, and non-legend (OTC) drugs will be the lowest of: 
a. Billed charge; 
b. EAC + special category fee C; 
c. Utah MAC + special category fee C; or 
d. AWP + special category fee not to exceed the maximum on the Federal upper limits 
list. 
e. Special Category fee C = $1.00 
2. Payment for non-legend OTC antacid liquids will be the lowest of: 
a. Billed charge: 
b. EAC + special category fee F; 
c. Utah MAC + special category fee F; or 
d. AWP J- special category fee not to exceed the maximum on the Federal upper limit 
list. 
Category fee F is calculated as follows: drug quantity + package size x $0.50 
3. Differential fee payment for select drugs reconstituted for Home I.V. infusion as typically 
prepared by a specialty pharmacy. Specialty pharmacies have low volume but high 
overhead expenses. The Department of Justice (DOJ) in year 2000 re-priced the AWP 
for 437 NDC specific products. The re-priced products necessitated four new dispensing 
fees. The four fees are defined as category J, category K, category L, and category M. 
T.N. # 09-00 l~ Approval Date 10-1-09 






S. PRESCRIBED DRUGS (Continued) 
Special Category Fees (Continued) 
Table 1 shows unit values assigned for each category to estabnsn tne Tee. An asiensK (*) 
equals one unit value. Items with two or more asterisks have a pigher value. 
Table 1 
Home Infusion Drug Categories 









B=$3 90, C=$1 00 
Category 'J' 
Category B or C 
plus 






dispensing fee J 
$8 90 
Category 'K' 
Category J plus 
**** clinical monitoring 
*** quality assurance 
*** labor factor 




pry 1 ' 
y K plus 
"Replacement into 
individual 
















ng fee L 
90 
Category 'M' 
Category L plus 
"Double gloves 
""Gown | 
"Vertical Hood I 







dispensing fee M 
$33 90 
The special category fee is a negotiated fee initially developed in cooperation with the Utah 
Pharmaceutical Association and other key pharmacists to apply to specific drugs historically 
advertised and dispensed to the general public at minimal prices. Tpis fee may be periodically 
changed to reflect changing market forces. 
T.N.# 09-001 
Supersedes T.N. # 01-004 
Approval Date 10-1-09 
Effective Date 3-1-09 
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S PRESCRIBED DRUGS (Continued) 
Rural Pharmacies 
In recognition of lower volume and higher acquisition costs, rural pharmacies are paid a $ 50 
dispensing fee differential The differential is paid in addition to the dispensing fee paid to 
urban pharmacies Rural is defined as those pharmacies located outside of Weber, Davis, 
Utah and Salt Lake counties 
T N # 93-002 Approval Date 5-21-93 
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Clinton C. Carter (Pro Hac Vice pending) C" \',^ 3 j p;< n.
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Telephone: (334) 269-2343 
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Joseph W. Steele (Bar No. 9697) 
Kenneth D. Lougee (Bar No. 10682) 
David C. Biggs (Bar No. 0321) 
Special Assistant Attorneys General 
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5664 South Green Street, Suite 300 
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Telephone: (801) 266-0999 
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Robert E. Steed (Bar No. 6036) 
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Telephone: (801) 281-1258 
Fax:(801)281-1250 
Attorneys for Plaintiff 
m THE THIRD JUDICIAL DISTRICT COTIRT OF 
SALT LAKE COUNTY 
STATE OF UTAH 
0 
THE STATE OF UTAH . 
SECOND AMENDED COMPLAINT 
„, . .„ AND JURY DEMAND 
Plaintiff, ' 
vs. Civil ^To. 080907678 
APOTEX CORPORATION; BAXTER J u d g e TB' r 0 I i e E- Medley 
INTERNATIONAL, INC.: BOEHRINGER 
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INGELHEIM CORPORATION; 
MALLINCKRODT, INC.; CSL BEHRING; 
FOREST LABORATORIES, INC.; 
MORTON GROVE PHARMACEUTICALS, 
INC.; MUTUAL PHARMACEUTICAL 
COMPANY, INC.; NOVARTIS 
PHARMACEUTICAL CORPORATION; 
PFIZER, INC.; QUALITEST 
PHARMACEUTICALS, INC.; SCHERING-
PLOUGH CORPORATION; SCHWARZ 
PHARMA US HOLDINGS, INC.; TARO 
PHARMACEUTICALS, U.S.A., INC.; 
UPSHER-SMITH, INC.; and WYETH, INC. 
Defendants. 
Plaintiff, the State of Utah ("State"), by and through its Attorney General Mark L. 
Shurtleff, files this Complaint against the above-named Defendants and alleges, on information 
and belief, the following: 
INTRODUCTION 
1, The Defendants have engaged in false, misleading, willful, unfair, and deceptive 
acts and practices in the pricing and marketing of their prescription drug products. The 
Defendants' fraudulent pricing and marketing of their prescription drugs have impacted elderly, 
disabled, and poor Utah citizens covered by the State's Medicaid program ("Utah Medicaid") by 
causing Utah Medicaid to pay grossly excessive prices for the Defendants' prescription drugs. 
Utah Medicaid is administered by the Division of Health Care Financing within the single state 
agency, the Utah Department of Health. 
2. Fair and honest drug pricing is a matter of great importance to the State and its 
citizens. Expenditures by the State for prescription drug reimbursement have increased 
dramatically in the past several years as a result, in part, of Defendants' fraudulent pricing 
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scheme. Each year Utah spends hundreds of millions of dollars on prescription drugs under the 
Utah Medicaid program. In fiscal year 2005 alone, Utah Medicaid spent $207,6 million on 
prescription drugs. Since 1990, Utah Medicaid prescription drug expenditures have increased 
exponentially. This increase in prescription drug costs in recent years has contributed to a health 
care funding crisis within the State that requires action to ensure fair dpaling between the 
Defendants and the State, 
3. The State is accountable to its citizens and taxpayers ad to how it spends limited 
State resources, and it is obligated to pursue any entity whose unlawful conduct has led to the 
overspending of State funds. Consequently, the State, by and through) Attorney General 
Shurtleff. brings this action to recover amounts overpaid for prescription drugs by Utah 
Medicaid, as a result of the fraudulent and willful conduct of Defendants. 1 he State further 
seeks to prohibit and permanently enjoin Defendants from continuing|to perpetrate their drug-
pricing scheme, to require Defendants to publicly disclose true drug pfcices, and to require 
Defendants to account for and disgorge all profits obtained by Defendants as a result of their 
improper and unlawful actions. 
4. This lawsuit seeks legal redress for the fraudulent and Willful pricing conduct of 
Defendants, who have profited from their wrongful acts and practicesi at the expense of the State. 
JURISDICTION AND VENUE 
5. Jurisdiction over the subject matter of this cause of actjion is based upon the False 
Claims Act, Title 26, Chapter 20 of the Utah Health Code, which provides remedies to redress 
Defendants5 actions under Utah Code Annotated § 26-20-1 et seq. 
6. Personal jurisdiction over these Defendants is proper Under the Utah Long Arm 
Statute as codified in §§ 78-27-22 and 78-27-24 of the Utah Code Annotated. 
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7. Venue is proper in the Third Judicial District and Salt Lake County pursuant to 
Utah Code Annotated § 78-13-7 in that many of the unlawful acts committed by Defendant were 
committed in Salt Lake County, including the making of false statements and misrepresentations 
of material fact to the State of Utah, its departments, agencies, instrumentalities and contractors, 
including the Utah Medicaid Program, and relied upon by Utah Medicaid to reimburse providers 
for the prescription drug needs of the Utah Medicaid recipients, 
PARTIES 
8. Plaintiff is the State of Utah. The State brings this action in its capacity as 
sovereign and on behalf of the Utah Medicaid Program. The Attorney General of the State of 
Utah, Mark L. Shurtleff, as chief law officer of the State of Utah is statutorily authorized to 
prosecute and maintain this action. 
DEFENDANTS 
Defendant Apotex 
9. Defendant Apotex Corp. ("Apotex") is a Florida corporation with its principal 
place of business located at 2400 North Commerce Parkway, Suite 400, Weston, FL 33326. 
Apotex is engaged in the business of manufacturing, distributing, marketing, and/or selling 
prescription drags that are reimbursed by Utah Medicaid. 
10. The Apotex drugs at issue in this case are identified in Exhibit A, attached. 
11 Defendant Apotex was involved in the sale, manufacture and pricing information 
for all drags as set forth in Exhibit A. 
12, Defendant Apotex made false publications for each drug identified in Exhibit A as 
follows: Apotex set, controlled and reported prices for said drugs to ihird-party compendia, 
including Firsi Databank. First Databank, in turn, published prices for Apotex to the State of 
A0120 
4 
Utah. These publications became relevant each and every time Utah reimbursed a provider for 
an Apotex drug between 1991 and 2006. The State actually relied upqn this false pricing 
information each and every time it reimbursed a provider. 
13. The State does not know the actual price that should halve been published. The 
published price should have been reflective of actual market prices, wjiich the Defendant keeps 
confidential. 
The Baxter Defendants 
14. Defendant Baxter International, Inc. ("Baxter International") is a Delaware 
corporation with its principal place of business located at One Baxter parkway. Deerfield, IL 
60015-4633. 
15. Defendant Baxter Healthcare Corporation ("Baxter Heklthcare"), a wholly-owned 
subsidiary of Baxter International, Inc., is a Delaware corporation [with its principal place of 
business located at One Baxter Parkway, Deerfield, IL 60015. 
16. Baxter International and Baxter Healthcare (collective^, the "Baxter Defendants") 
are diversified healthcare companies that individually, and/or in combination with one another, 
engage in the business of manufacturing, distributing, marketing, | 
drugs that are reimbursed by Utah Medicaid. 
17. The Baxter Defendants drugs at issue in this case are identified in Exhibit A, 
attached. 
18. The Baxter Defendants were involved in the sale, manufacture and pricing 
information for all drugs as set forth in Exhibit A. 
19. The Baxter Defendants made false publications for ealch drug identified in Exhibit 
A as follows: Baxter Defendants set, controlled and reported prices for said drugs to third-party 
and/or selling prescription 
5 
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compendia, including First Databank First Databank, in turn, published prices for Baxter to the 
State of Utah These publications became relevant each and every time Utah reimbuised a 
provider for a Baxter Defendant drug between 1991 and 2006 The State actually relied upon 
this false pncing information each and every time it reimbursed a provide: 
20 The State does not know the actual price that should have been published The 
published price should have been reflective of actual maiket prices, which the Defendants keep 
confidential 
The Boehringer Defendants 
21 Defendant Boehringer Ingelheim Corporation ("BIC) is a Kevada corpoiation 
with its principal place of business located at 900 Ridgebury Road, Ridgefield, CT 06877 
Boehringer includes a number of subsidiary companies that manufacture, distribute, market, 
and/or sell preset lption drugs 
22 Defendant Boehrmgei Ingelheim Pharmaceuticals, Inc (^BIPI") is a Delaware 
corporation with its principal place of busmess located at 900 Ridgebury Road, Ridgefield, CT 
06877 
23 Defendant Roxane Laboratories, Inc (' BIRT) is a Delaware corpoiation with its 
principal place of business located at 1809 Wilson Road, Columbus. OH 43228-9579 
24 BIC, BIPI and BIRI (collectively "the Boehringer Defendants"; are diversified 
healthcare companies that individually, and/oi m combination vsith one another, engage in the 
busmess of manufacturing, distributing, marketing, and/or selling prescription drugs that aie 
reimbursed by Utah Medicaid 




26. The Boehringer Defendants were involved in the sale, ipianutacture ana pricing 
information for all drugs as set forth in Exhibit A. 
27. The Boehringer Defendants made false publications fot each drug identified in 
Exhibit A as follows: The Boehringer Defendants set controlled and (reported prices for said 
drugs to third-party compendia, including First Databank. First Databank, in turn, published 
prices for the Boehringer Defendants to the State of Utah. These publications became relevant 
each and every time Utah reimbursed a provider for a Boehringer Defendant drug between 1991 
and 2006. The State actually relied upon this false pricing informatioh each and every time it 
reimbursed a provider. 
28. The State does not know the actual price that should haVe been published. The 
published price should have been reflective of actual market prices, vltfiich the Defendants keep 
confidential. 
Defendant CSL Behring 
29. Defendant CSL Behring (nCSL") is a Pennsylvania corporation with its principal 
place of business located at 1020 First Avenue, King of Prussia, PA 19406. CSL is engaged in 
the business of manufacturing, distributing, marketing, and/or sellinb prescription drugs that are 
reimbursed by Utah Medicaid. 
30. The CSL drugs at issue in this case are identified in Exhibit A, attached. 
31. Defendant CSL was involved in the sale, manufacture and pricing information for 
all drugs as set forth in Exhibit A. 
32. Defendant CSL made false publications for each drug| identified in Exhibit A as 
follows: CSL set, controlled and reported prices for said drugs to thitd-party compendia, 
including First Databank. First Databank, in turn, published prices f6r CSL to the State of Utah. 
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These publications became relevant each and every time Utah reimbursed a provider for a CSL 
drug between 1991 and 2006. The State actually relied upon this false pricing information each 
and every time it reimbursed a provider. 
33. The State does not know the actual price that should have been published. The 
published price should have been reflective of actual market prices, which the Defendant keeps 
confidential, 
The Forest Defendants 
34. Defendant Forest Laboratories, Inc. ("Forest") is a Delaware corporation with its 
principal place of business located at 909 Third Avenue, New York, NY 10022. 
35. Defendant Forest Pharmaceuticals, Inc. ("Forest Pharm"), wholly-owned 
subsidiary of Forest, is a Delaware corporation with its principal place of business located at 
13600 Shoreline Drive, St. Louis, MO 63045. 
36. Forest and Forest Pharm (collectively, the "Forest Defendants") are diversified 
healthcare companies that individually, and/or in combination with one another, engage in the 
business of manufacturing, marketing, distributing, and/or selling prescription drugs that are 
reimbursed by Utah Medicaid. 
37. The Forest Defendants drugs at issue in this case are identified in Exhibit A, 
attached. 
38. The Forest Defendants were involved in the sale, manufacture and pricing 
information for all drugs identified in Exhibit A. 
39. The Forest Defendants made false publications for each drug identified in Exhibit 
A as follows: Forest Defendants set, controlled and reported prices for said drugs to third-party 
compendia, including First Databank. First Databank, in turn, published prices for the Forest 
8 A0124 
Defendants to the State of Utah. These publications became relevant each and every time Utah 
reimbursed a provider for a Forest Defendants drug between 1991 and 2006. The State actually 
relied upon this false pricing information each and every time it reimbursed a provider. 
40. The State does not know the actual price that should nave been published. The 
published price should have been reflective of actual market prices, which the Defendant keeps 
confidential. 
Defendant Mallinckrodt 
41. Defendant Mallinckrodt, Inc. ("Mallinckrodt") is a Missouri corporation with its 
Hazelwood, MO 63042. 
, marketing, and/or selling 
principal place of business located at 675 McDonnell Blvd., 
Mallinckrodt is engaged in the business of manufacturing, distributin 
prescription drugs that are reimbursed by Utah Medicaid. 
42. The Mallinckrodt drugs at issue in this case are identified in Exhibit A, attached 
43. Defendant Mallinckrodt was involved in the sale, manufacture and pricing 
information for all drugs as set forth in Exhibit A. 
44. Defendant Mallinckrodt made false publications for eabh drag identified in 
Exhibit A as follows: Mallinckrodt set, controlled and reported prices for said drugs to third' 
party7 compendia, including First Databank. First Databank, in turn, published prices for 
Mallinckrodt to the State of Utah. These publications became relevant each and every time Utah 
reimbursed a provider for a Mallinclcrodt drug between 1991 and 200p. The State actually relied 
upon this false pricing information each and every time it reimbursed 
45. The State does not know the actual price that should) 
published price should have been reflective of actual market prices, 
confidential. 
a provider. 
have been published. The 
which the Defendant keeps 
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Defendant Morton Grove 
46. Defendant Morton Grove Pharmaceuticals, Inc. ("Morton") is an Illinois 
corporation with its principal place of business located at 6451 W Main Street, Morton Grove, IL 
60053. Morton is engaged in the business of manufacturing, distributing, marketing, and/or 
selling prescription drugs that are reimbursed by Utah Medicaid. 
47. The Morton drugs at issue in this case are identified in Exhibit A, attached. 
48. Defendant Morton was involved in the sale, manufacture and pricing information 
for all drugs as set forth in Exhibit A. 
49. Defendant Morton made false publications for each drug identified in Exhibit A 
as follows: Morton set, controlled and reported prices for said drugs to third-party compendia, 
including First Databank. First Databank, in turn, published prices for Morton to the State of 
Utah. These publications became relevant each and every time Utah reimbursed a provider for a 
Morton drug between 1991 and 2006. The State actually relied upon this false pricing 
information each and every time it reimbursed a provider. 
50. The State does not know the actual price that should have been published. The 
published price should have been reflective of actual market prices, which the Defendant keeps 
confidential. 
Defendant Mutual 
51. Defendant Mutual Pharmaceutical Company ("Mutual") is a Pennsylvania 
corporation with its principal place of business located at 1100 Orthodox Street, Philadelphia, 
PA 19124. Mutual is engaged in the business of manufacturing, distributing, marketing, and/or 
selling prescription drugs that are reimbursed by Utah Medicaid. 
52. The Mutual drugs at issue in this case are identified in Exhibit A, attached. 
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53. Defendant Mutual was involved in the sale, manufacture and pricing information 
for all drugs identified in Exhibit A. 
54. Defendant Mutual made false publications for each driig identified in Exhibit A as 
follows: Mutual set, controlled and reported prices for said drugs to third-party compendia, 
including First Databank First Databank, in turn, published prices for Mutual to the State of 
Utah. These publications became relevant each and every time Utah reimbursed a provider for a 
Mutual drug between 1991 and 2006. The State actually relied upon this false nricing 
information each and every time it reimbursed a provider. 
5 5. The State does not know the actual price that should hive been published. The 
published price should have been reflective of actual market prices. vi\ 
confidential. 
hich the Defendant keeps 
Defendant Novartis 
56. Defendant Novartis Pharmaceuticals Corporation ("No\f 
corporation with its principal place of business located at One Health 
07936-1080. 
artis") is a Delaware 
Plaza, East Hanover, NJ 
57. Novartis engages in the business of manufacturing, distributing, marketing, and/or 
selling prescription drugs that are reimbursed by Utah Medicaid. 
58. Novartis drugs at issue in this case are identified in ExhJibit A, attached. 
59. Novartis was involved in the sale, manufacture and priqing information for ail 
drugs identified in Exhibit A. 
60. Novartis made false publications for each drug identified in Exhibit A as follows. 
Novartis set, controlled and reported prices for said drugs to third-party compendia, including 
First Databank. First Databank, in turn, published prices for Novartis to the State of Utah. 
11 
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These publications became relevant each and every time Utah reimbursed a provider for Novartis 
drugs between 1991 and 2006, The State actually relied upon this false pricing information each 
and every time it reimbursed a provider. 
61. The State does not know the actual price that should have been published. The 
published price should have been reflective of actual market prices, which the Defendant keeps 
confidential. 
The Pfizer Defendants 
62. Defendant Pfizer. Inc. ("Pfizer") is a Delaware corporation with its principal place 
of business located at 235 East 42nd Street New York? NY 10017. With the merger of Pfizer 
and Pharmacia Corporation in 2003, Pfizer became the largest drug company in the world today. 
63. Defendant Pharmacia Corporation ("Pharmacia") is a Delaware corporation with 
its principal place of business located at 235 East 42na Street, New York, NY 10017-5755. 
64. Defendant Pharmacia & Upjohn Company Corporation ("P & U"), a subsidiary of 
Pharmacia Corporation, is a Delaware corporation with its principal place of business located at 
235 E. 42nd Street, New York, NY 10017-5703. 
65. Pfizer, Pharmacia and P & U (collectively, the "Pfizer Defendants") are diversified 
healthcare companies that individually, and/or in combination with one another, engage in the 
business of manufacturing, distributing, marketing, and/or selling prescription drugs that are 
reimbursed by Utah Medicaid. 
66. The Pfizer Defendants drugs at issue in this case are identified in Exhibit A, 
attached. 
67. The Pfizer Defendants were involved in the sale, manufacture and pricing 
information for all drugs as set forth in Exhibit A. 
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68, The Pfizer Defendants made false publications for each drug identified in Exhibit 
A as follows: Pfizer Defendants set, controlled and reported prices for said drugs to third-party 
compendia, including First Databank. First Databank, in turn, published prices for the Pfizer 
Defendants to the State of Utah. These publications became relevant each and every time Utah 
reimbursed a provider for the Pfizer Defendants drug between 1991 and 2006, The State actually 
relied upon this false pricing information each and every time it reimbursed a provider. 
69. The State does not know the actual price that should have been published. The 
published price should have been reflective of actual market prices, w|l 
confidential. 
Defendant Qualitest Pharmaceuticals, Inc 
liich the Defendant keeps 
70. Defendant Qualitest Pharmaceuticals, Inc. ("Qualitest") is an Alabama corporation 
with its principal place of business located at 130 Vintage DR NE, Hunts ville, AL 35811. 
Qualitest is engaged in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by Utah Medicaid. 
71. The Qualitest drugs at issue in this case are identified in exhibit A, attached. 
72. Defendant Qualitest was involved in the sale, manufacture and pricing information 
for all drugs as set forth in Exhibit A. 
73. Defendant Qualitest made false publications for eacn drug laentitiea in Exhibit A 
as follows: Qualitest set, controlled and reported prices for said drugs to third-party compendia, 
including First Databank. First Databank, in turn, published prices for Qualitest to the State of 
Utah. These publications became relevant each and every time Utah reimbursed a provider for a 
Qualitest drug between 1991 and 2006. The State actually relied upq>n this false pricing 
information each and every time it reimbursed a provider. 
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74. The State does not know the actual price that should have been published. The 
published price should have been reflective of actual market prices, which the Defendant keeps 
confidential. 
The Schering Defendants 
75. Defendant Schering-Plough Corporation ("Schering-Plough") is a New Jersey 
corporation with its principal place of business located at 2000 Galloping Hill Road, Kenilworth, 
NJ 07033, 
76. Defendant Warrick Pharmaceuticals Corporation ("Warrick"), a w?holly-owned 
subsidiary of Schering-Plough, is a Delaware corporation with its principal place of business 
located at 12125 Moya Blvd., Reno, NV 89506-2600, 
77. Schering-Plough and Warrick (collectively, the "Schering Defendants") are 
diversified healthcare companies that individually, and/or in combination with one another, 
engage in the business of manufacturing, distributing, marketing, and/or selling prescription 
drugs that are reimbursed by Utah Medicaid. 
78. The Schering Defendants drugs at issue in this case are identified in Exhibit A} 
attached, 
79. The Schering Defendants were involved in the sale, manufacture and pricing 
information for all drugs as set forth in Exhibit A. 
80. The Schering Defendants made false publications for each drug identified in 
Exliibit A as follows: Schering Defendants set. controlled and reported prices for said drugs to 
third-party compendia, including First Databank. First Databank, in turn, published prices for 
the Schering Defendants to the State of Utah. These publications became relevant each and 
every time Utah reimbursed a provider for the Schering Defendants drug between 1991 and 
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2006 The State actually relied upon this false pricing information eac^ h and every time it 
reimbursed a provider. 
81. The State does not know the actual price that should hav|e been published. The 
published price should have been reflective of actual market prices, which the Defendant keeps 
confidential. 
Defendant Schwarz 
82. Defendant Schwarz Pharma USA Holdings, Inc. ("Schvjarz") is a Delaware 
corporation with its principal place of business located at 103 Foulk Rd Suite 202, Wilmington, 
DE 19803. Schwarz is a wholly-owned U.S. subsidiary of Schwarz Fharma AG, a German 
corporation with its principal place of business located at Alfred-Nobtl-StraBe, 10 Monheim, 
Geimany. Schwarz is engaged in the business of manufacturing, distributing, marketing, and/or 
selling prescription drugs that are reimbursed by Utah Medicaid, 
83. The Schwarz drugs at issue in this case are identified iji Exhibit A, attached. 
84. Defendant Schwarz was involved in the sale, manufacture and pricing information 
for all drugs as set forth in Exhibit A. 
8 5. Defendant Schwarz made false publications for each drug identified in Exhibit A 
as follows: Schwarz set, controlled and reported prices for said drugs to third-party compendia, 
including First Databank. First Databank, in turn, published prices for Schwarz to the State of 
Utah. These publications became relevant each and every time Utah 
Schwarz drug between 1991 and 2006. The State actually relied upop this false pricing 
information each and every time it reimbursed a provider. 
reimbursed a provider for a 
A0131 
15 
86. The State does not know the actual price that should have been published. The 
published price should have been reflective of actual market prices, which the Defendant keeps 
confidential. 
Defendant Taro 
87. Defendant Taro Pharmaceuticals U.S.A., Inc. ('Taro"), a New York corporation 
with its principal place of business located at 3 Skyline Drive, Hawthorne, NY 10532. Taro is 
engaged in the business of manufacturing, distributing, marketing, and/or selling prescription 
drugs that are reimbursed by Utah Medicaid. 
88. The Taro drugs at issue in this case are identified in Exhibit A, attached. 
89. Defendant Taro was involved in the sale, manufacture and pricing information for 
all drugs as set forth in Exhibit A. 
90. Defendant Taro made false publications for each drug identified in Exhibit A as 
follows: Taro set, controlled and reported prices for said drugs to third-party compendia, 
including First Databank. First Databank, in turn, published prices for Taro to the State of Utah. 
These publications became relevant each and every time Utah reimbursed a provider for a Taro 
drug between 1991 and 2006. The State actually relied upon this false pricing information each 
and every time it reimbursed a provider. 
91. The State does not know the actual price that should have been published. The 
published price should have been reflective of actual market prices, which the Defendant keeps 
confidential. 
Defendant Upsher-Smith 
92. Defendant Upsher-Smith, Inc. ("Upsher-Smith") is a Minnesota coiporation with 
its principal place of business located at 13700 1st Ave, N, Minneapolis, MN 55441. Upsher-
16 
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Smith is engaged in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by Utah Medicaid. 
93. The Upsher-Smith drugs at issue in this case are identified in Exhibit A, attached. 
94. Defendant Upsher-Smith was involved in the sale, manufacture and pricing 
information for all drugs as set forth in Exhibit A. 
95. Defendant Upsher-Smith made false publications for eich drug identified in 
Exhibit A as follows: Upsher-Smith set, controlled and reported prices for said drugs to third-
party compendia, including First Databank. First Databank, in turn, published prices for Upsher-
Smith to the State of Utah. These publications became relevant each and every time Utah 
reimbursed a provider for an Upsher-Smith drug between 1991 and 2006. The State actually 
relied upon this false pricing information each and every time it reimbursed a provider. 
96. The State does not know the actual price that should have been published. The 
published price should have been reflective of actual market prices, wpich the Defendant keeps 
confidential. 
Home Products Corp., is a 
The Wyeth Defendants 
97. Defendant Wyeth, Inc. ("Wyeth"), formerly Americanl! 
Delaware corporation with its principal place of business located at Five Giralda Farms, 
Madison, NJ 07940. 
98. Defendant Wyeth Pharmaceuticals, Inc. ("Wyeth Pharm"), a division of Wyeth, is 
a Delaware corporation with its principal place of business located at 
Collegeville, PA 19426. 
500 Areola Road, 
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99. Wyeth and Wyeth Pharm (collectively, the "Wyeth Defendants") are diversified 
healthcare companies that individually, and/or in combination with one another, engage in the 
business of manufacturing, distributing, marketing, and/or selling prescription drugs that are 
reimbursed by Utah Medicaid. 
100. The Wyeth Defendants drugs at issue in this case are identified in Exhibit A, 
attached. 
101. The Wyeth Defendants were involved in the sale, manufacture and pricing 
information for all drugs as set forth in Exhibit A. 
102. The Wyeth Defendants made false publications for each drug identified in Exhibit 
A as follows, Wyeth Defendants set, controlled and reported prices for said dmgs to third-party 
compendia, including First Databank. First Databank, in turn, published prices for the Wyeth 
Defendants to the State of Utah. These publications became relevant each and every time Utah 
reimbursed a provider for a Wyeth Defendants drug between 1991 and 2006. The State actually 
relied upon this false pricing information each and every time it reimbursed a provider. 
103. The State does not know the actual price that should have been published. The 
published price should have been reflective of actual market prices, which the Defendant keeps 
confidential. 
NATURE OF THE CASE 
104. This is a civil action for damages and civil penalties pursuant to the Utah False 
Claims Act, Utah Code Annotated §26-20-1, et seq., and Utah Common Law No Federal 
Claims are asserted and are hereby expressly disavowed. 
FACTUAL BACKGROUND 
The Utah Medicaid Program 
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105. The Utah Medicaid program is a state-administered program with federal 
matching funds, which pays for medical care, including prescription drug benefits, for Utah's 
low-income and disabled citizens. The Utah Medicaid program currently covers approximately 
300,000 individuals. The prescription drug benefit cost has increased dramatically in recent 
years from S47.5 million in 1996 to $207.6 million in 2005, an increase of 437% in nine years or 
a compounded annual rate of 17.8%. 
106. Utah Medicaid reimburses medical providers, including physicians and 
pharmacists, for drugs prescribed for, and dispensed to, Utah Medicaid recipients pursuant to 
statutory and administrative formulas. 
107. Reimbursement for pharmacy-dispensed prescription drugs under the Utah 
Medicaid program is based on information supplied by Defendants to industry reporting services. 
This information includes the following price indices; (i) Average Wholesale Price ("AWP"), 
which is commonly understood as the average price paid by retailers, such as hospitals, doctors 
and pharmacies to wholesalers, for prescription drugs and (ii) Wholesale Acquisition Cost 
("WAC"), which is commonly understood as the price paid by wholesalers to the manufacturers 
for prescription drugs. At all times relevant to this action, Defendants were aware of Utah 
Medicaid's drug reimbursement formulas and procedures for pharmacy-dispensed drugs. 
108. Under the federal Medicaid requirements, the State must submit plans for Utah's 
Medicaid programs to the federal government for approval. Those plans must 
[p]rovide such methods and procedures relating to the utilization of, and the 
payment for, care and services available under the plan as may be necessary 
to safeguard against unnecessary utilization of such care and Services and to 
assure that payments are consistent with efficiency, economy, and quality of care 
and are sufficient to enlist enough providers so that care and sendees are available 
under the plan at least to the extent that such care and service? are available to the 
general population in the geographic area. 
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42 U S C § 1396a(a)(30)(A)(emphasis added) The federal Medicaid regulations limit Utah 
reimbursements foi prescription drugs The regulations distinguish between ''brand name drugs " 
which are still under patent protection, and "multiple souice" (also called "generic*5) drugs, 
winch enter the marketplace after the patent on the biand-name drug expires 
109 Brand-name drugs Utah Medicaid leimbuisements to provideis for brand-name 
drugs "must not exceed, in the aggregate, payment levels that the agency has determined by 
applying the lowei of the (1) [estimated acquisition costs plus reasonable dispendmg fees 
established by the agency or (2) [providers' usual and customary charges to the general public ' 
42 C F R § 447 331(b) ] "Estimated acquisition cost" means the agenc) *s "best estimate of the 
price generally and currently paid by pioviders for a drug marketed or sold by a particular 
manufactuiei oi labeler in the package size of drug most frequently purchased by providers " 42 
C F R § 447 302 "Reasonable dispensing fee" means the fee that is "mcuired at the point of sale 
oi service and pays for costs in excess of the ingredient cost of a covered outpatient drug each 
time a covered outpatient diug is dispensed " Id 
110 Although the Defendants may attempt to obfuscate this regulation, it could not be 
clearer It forbids Utah Medicaid from deliberately setting the "estimated acquisition costs5 of 
drugs at levels which give providers as a group a systematic "spread5 over what it costs them to 
acquire drugs Setting "estimated acquisition cost at such levels would cause Utah s Medicaid 
total leimbursements for brand-name drugs to exceed the sum of "estimated acquisition cosf 
plus the reasonable dispensing fees as determined by the agency Regaidless of hovs much 
piessure an agency feels to initiate its "estimated acquisition cost" to piovide piofit 10 pro\iders 
1
 The provider's "reasonable and customary" charge is normaJ) the list puce tha* providers like pharmacies 
charge purchasers who aie not entitled to the discounts that aie customarily demandec and recen ea b) third party 
payers such as private insuiers, Medicare, or Medicaid See V S i Bruno s Jnc 54 F Supp 2d 1252 1256-58 (MI 
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such inflation cannot be reconciled with these regulations. "Congress inacted Title XIX of the 
Social Security Act [which includes Medicaid] to care for the poor ancfl aged, not to subsidize or 
otherwise to benefit health care providers.55 
111. Generic drugs. For many "generic" or multiple soured drugs, the federal Center 
for Medicare and Medicaid Services (CMS) has set what is called a "Federal Upper Limit" 
(FUL) - a maximum amount that states may not exceed in reimbursing providers of the drugs 
subject to the FUL. Where CMS has set a FUL for a particular drug, federal regulations have 
provided, during most times relevant to this suit, that Utah Medicaid cannot pay more in the 
aggregate for these drugs than that FUL plus a reasonable dispensing fee. See 42 C.F.R. § 
447.331, 332 (1999), now modified and renumbered as 42 C.F.R. § 447.512(a). 
112. Unlike the concept of "estimated acquisition cost" as defined by the federal 
regulations, the concept of the FUL is not designed to forbid a profit to providers. To the 
contrarys the FUL, which applies to generic drugs, may provide for some degree of profit to the 
provider as an incentive to induce the provider to dispense a cheaper generic drug rather than the 
more expensive brand-name version. But the FUL is a ceiling, not a flc 
pay. As discussed below, Utah is unwilling to pay the FUL for a drug : 
"estimated acquisition cost" is lower. 
113. As contemplated by the federal scheme, the State of Uxah has set reimbursement 
levels for prescription drugs under the Medicaid program, through regulations issued by the Utah 
Department of Health, Division of Health Care Financing ("DHCF"). No Utah statute or 
regulation tells the DHCF to set reimbursement rates at levels that would provide a systematic 
|oor, on what a state can 
if the provider's 
Ala. 1999). It is relatively uncommon for a provider's "usual and customary" chargp to be lower than the sum of 
"estimated acquisition cost" and the dispensing fee.v 
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"profit" for pharmacists or other providers, and as shown, above, federal regulations prohibit a 
systematic profit from being built into "estimated acquisition cost." 
114. Between 1991 and 2006, DHCPs regulation provided that the State would 
reimburse for any drug by paying the drug's "estimated acquisition cost" plus the dispensing fee, 
unless the drug in question had a FUL that was lower than the estimated acquisition cost, in 
which case the DHCF would pay the FUL plus the dispensing fee. In 1989, Utah created a 
"Maximum Allowable Cost" (MAC) program for certain drugs. Since then, the regulation has 
provided that the State will pay the lowest of estimated acquisition cost the FUL (if one exists 
for a drug), or the MAC (if one exists for a drug), plus, in any of the three cases, the reasonable 
dispensing fee. In any event, the price cannot exceed the usual and customary charge (billed 
charged) to the general public. Utah's MAC program had very limited use until November of 
2008, at which time it was expanded due to budget constraints. 
115. The Defendants5 inflated AWPs were the only variable in the formulas used by 
the State to reimburse brand name drugs. Thus, had the Defendants' AWPs been lower, the 
amounts the State would have paid for brand name drugs would have been correspondingly 
lower as a matter of arithmetic. 
116. Defendants' AWPs were an essential variable in deciding what the lowest price 
was in the formula for reimbursing generic drugs - i.e., the State would pay the lowest of the 
acquisition cost as estimated through AWT, the Federal Upper Limit if it existed for the drug in 
question, or the State's Maximum Allowable Cost if it existed for the drug. MAC prices or 
reimbursement rates are a schedule of pricing for generically equivalent drugs based upon the 
listed AWPs of competing generic drug manufacturers. Generic drug makers are able to push 
market share for their generic drugs by intentionally increasing the published AWT for a generic 
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estimated acquisition cost 
:o make that comparison 
drug with the intention to create a profit margin for others in the distribution chain. That profit 
margin is taken advantage of either directly (through reimbursement based upon AWP) or 
indirectly on the AWP based upon the establishment of a MAC tied to the AWP. 
117. The State would have reimbursed on the basis of "estimated acquisition cost" if 
that cost had been the lowest of these three measures. But because the 
was inflated by Defendants5 inflated AWPs, the State lost the chance 
and save itself money. 
The Defendants' Reporting of Inflated Pricing Information 
118. Defendants knowingly, willfully, wantonly, and/or intentionally provided, or 
caused to be provided, false and inflated AWP, WAC, and/or other pricing information for their 
drugs to various nationally known drug industry reporting services, including First DataBank 
(a/k/a Blue Book), Medical Economics, Inc. (a/k/a Red Book), and Mpdispan (collectively 
referred to herein as "various nationally known drug industry reporting services" or "reporting 
services'5)- These reporting services published the pricing information to various reimbursers, 
such as Utah Medicaid, who have contracted to receive the information (either in electronic or 
hard copy form) as a basis to provide reimbursement to the medical o^ pharmacy providers who 
provide the drugs to patients. 
119. Utah Medicaid purchased and utilized the Defendants5 (published AWT, WAC, 
and other pricing information from First DataBank (Blue Book), and Medical Economics, Inc. 
(Red Book). The information from Blue Book was and is used by Utah Medicaid with respect to 
reimbursement for pharmacy-dispensed drugs. At all relevant times to this action, Utah 
Medicaid relied upon the AWT, WAC, and/or other pricing information provided by Defendants 
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to the industry reporting services in determining the amount Utah Medicaid reimburses 
providers. 
120. Defendants knew the false and deceptive inflation of AWP, WAC, and/or other 
pricing information for their drugs would cause Utah Medicaid to pay excessive amounts for 
these drugs. Defendants' inflated AWPs and WACs greatly exceeded the actual prices at which 
drugs were sold to retailers (physicians, hospitals, and pharmacies) and wholesalers. 
Defendants' reported AWPs and WACs were false and misleading and bore no relation to any 
price, much less a wholesale or retail price. 
121. Defendants knowingly, willfully, wantonly, and/or intentionally concealed the 
true prices for their respective drugs, by trick or artifice, from Utah Medicaid. At all times 
relevant, each Defendant knew its own true prices which were not reported to the industry 
reporting services for use by state Medicaid agencies. Each Defendant also knew whether the 
price reported to the reporting services accurately and truthfully represented the actual prices as 
reflected by market experience and conditions. At all times pertinent, the Defendants' 
concealment of the true prices hindered Utah Medicaid from obtaining or knowing the true 
prices. Furthermore, the Defendants concealed the true prices knowing that Utah Medicaid 
relied upon the false reported prices. 
122. Unless governmental or industry surveys, lawsuits, or criminal or regulatory 
investigations publicly reveal the true AWT or WAC for a particular drug at issue, Utah 
Medicaid is not privy to the actual market prices which it can then compare against the reported 
prices. Defendants have concealed true market pricing information from Utah Medicaid for the 
purpose of avoiding detection of the fraudulent scheme described herein. 
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123, Defendants used undisclosed discounts, rebates and other inducements, which had 
the effect of lowering the actual wholesale or retail prices paid by wholesalers and retailers as 
compared to the reported prices. In addition, Defendants employed secret agreements to conceal 
the lowest prices paid for their pharmaceutical products. As a result of these concealed 
inducements, Defendants have prevented third parties, including Utah| Medicaid, from 
determining the true prices paid by wholesalers and retailers. 
FIRST CLAIM FOR RELIEF 
(Restitution, Costs and Civil Penalties under the Utah Flalse Claims Act) 
124. Plaintiff incorporates paragraphs 1 through 129 as if fully set forth herein, and 
further alleges as follows: 
125. Defendants violated the False Claims Act as codified iji the Utah Health Code at 
Title 26, Chapter 20 of the Utah Code Annotated. Defendants issued false and inflated AWP, 
WAC, and/or other pricing information for publication by the industry reporting services, in 
violation of Utah Code Annotated §§ 26-20-3, 26-20-4 and 26-20-7. Because of Defendants5 
fraudulent conduct and misrepresentations, Utah Medicaid relied on tne false information in 
reimbursing providers for Medicaid drugs. Defendants "knowingly" acted in deliberate 
ignorance or reckless disregard of the truth, and in so doing, caused the State to pay false claims 
due to the grossly reimbursements for Defendants' prescription drugs 
126. Defendants' "false representation" regarding the price 
"material fact for use in determining rights to a medical benefit," and|-
Annotated §26-20-3(2). 
127. According to U.C.A, 26-20-4, it is illegal to pay a kickback to induce the 
"purchasings leasing, or ordering of any goods or services for which payment is or may be made 
of their drugs was a 
a violation of Utah Code 
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in whole or in part pursuant to a medical benefit program " Utah Code Annotated § 26-20-
4(2)(a)(emphasis added). The discounts, rebates and other price concessions paid by Defendants 
to providers are clearly considered "kickbacks", which is defined by U.C.A. 26-20-4(1) as 
"rebates, compensation, or any other form of remuneration." 
128. The claims at issue were made for the medical benefit of Utah Medicaid 
recipients. By injecting false prices into Utah's reimbursement process, the Defendants directed 
others to submit claims which led to false reimbursements. Each and every Defendant derived 
benefits directly from the State, in that the State's Medicaid expenditures ultimately ended up in 
the pockets of the Defendants.2 
129. The false prices reported by Defendants5 "caused to be made or presented to an 
employee or officer of the State a claim for a medical benefit" in violation of U.C.A. § 26-20-
7(1). Specifically, the Defendants knew their false prices would result in the presentation of 
claims that are, "wholly or partially false, fictitious, or fraudulent", in violation of U.C.A. § 26-
20-7(1 )(a)> and would "represent charges at a higher rate than those charged by the provider to 
the general public," in violation of U.C.A. § 26-20-7(l)(d). 
130. Defendants also "retained unauthorized payment as a result of acts5* described in 
U.C.A. § 26-20-7. 
131. Under Utah Code Annotated § 26-20-9.5, Defendant is liable for the following 
damages: 
a. Full and complete restitution to the State of all damages that the State sustained; 
b. the costs of enforcement, including but not limited to the cost of investigators and 
attorneys; 
2
 Industry Facts-at-a-Glance, National Association of Chain Drug Stores (NACDS), 
http7/wvvr\v.nacds.org/wi-nspage.cfmf>parml=5Q7 (accessed March 26, 2009). 
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c, a civil penalty equal to three times the restitution amouht: and 
d. a civil penalty of $5,000 to $ 10,000 for each false clainfc filed. 
132. These costs and penalties are in addition to and not a substitute tor other damages 
caused by Defendants5 actions. 
SECOND CLAIM FOR RELIEF 
(Fraudulent Misrepresentation) 
133. Plaintiff incorporates paragraphs 1 through 138 as if fijlly set forth herein, and 
further alleges as follows: 
134. Defendants committed fraud against the State and its single state agency 
administering Utah Medicaid, the Utah Department of Health. Defendants reported or caused to 
be reported false AWP, WAC and/or other pricing information for their respective products on a 
periodic and continuing basis for publication and dissemination to third party payers, including 
Utah Medicaid and other state Medicaid programs. Defendants knew that the AWP, WAC and/or 
other pricing information that they provided and caused to be reported was false and material to 
the determination of Utah Medicaid reimbursement rates. 
135. Defendants misrepresented the pricing information wr 
Utah Medicaid to rely on the false information in setting prescription 
136. Utah Medicaid reasonably relied on the false pricing 
drug reimbursement rates and making payment based on said rates, 
misrepresentations are continuing, as they regularly and periodically 
.]th the intent of inducing 
drug reimbursement rates, 
data in setting prescription 
Defendants' 
continue to issue false and 
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inflated AWP. WAC and/or pricing information for publication by the industry reporting 
services. 
137. As a result of Defendants' fraudulent conduct, the State has been damaged by-
paying grossly excessive amounts for Defendants' prescription drugs. 
138. By engaging in the acts and practices described above, the Defendants have 
engaged and continue to engage in repeated fraudulent acts and practices in violation of Utah 
common law7. 
139. Defendants' conduct was and is knowing, intentional, gross, oppressive, 
malicious, wanton, and/or committed with the intention to cause injury. These actions subject 
Defendants to an award of punitive damages sufficient to punish the Defendants and deter others 
from similar fraudulent conduct. 
JURY DEMAND 
The State respectfully requests a trial by jury pursuant to Rule 38, Utah R. Civ. Proc. 
PRAYER FOR RELIEF 
Wherefore, Plaintiff, the State of Utah, prays for relief as follows: 
1. For costs of enforcement pursuant to § 26-20-9.5(2)(b), Utah Code Ann.; 
2. For an award of full and complete restitution to the State in such amount as is 
proved at trial; 
3. For punitive damages for the wanton and reckless conduct as outlined herein and 
as an example for the benefit of ail other drug manufacturers that wrongly 
misrepresent the prices of their products to the detriment of Utah Medicaid; 
4. For civil penalties pursuant to § 26-20-9.5(2)(c). Utah Code Ann., equal to: 
a. Three times the restitution amount; and 
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b. $5,000 to $ 10,000 for each false claim filed with Utah Medicaid. 
5. For an award of costs and prejudgment interest; and 
6. For such other and further relief as may be justified kid which Plaintiff may be 
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Through the following list, the State of Utah intends to capture not only the drug names 
listed, but also all variations of the drug names which incorporate prefixes, suffixes, modifiers, 




























































































































































































































































































































































































































































SODIUM POLY SULFONATE 
SODIUM CHLORIDE 


























M V I PED 
MONOCLATE 
IMONONINE 
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PHOSPH I O ~ 
PHOSPHOLIN" 
PIPRACIL ~ 
PIROXICAM"" 
PNU-IMUNE~ 
PONDIMIN ~ 
POSTURE 
POTASSIUM"-
[PRAZOSIN H 
IPREDNISONE 
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EXHIBIT A 
PREMARIN 
PREMPHASE 
PREMPRO 
PRENATAL PLUS 
PRIMATENE 
PRISTIQ EX 
PROBENECID 
PROCHLORPER 
PROMETHAZINE 
PROPOXYPHENE 
PROPRANOLOL 
PROPYLTHIOURACIL 
PROSTEP 
PROTONIX 
PYRAZINAMIDE 
QU1N1DEX 
jQUINIDINE 
IRAPAMUNE 
REGLAN 
RHEUMATREX 
RIOPAN 
ROBAXIN 
ROBAXISAL 
ROBICILLIN 
ROBIMYCIN 
ROB1NUL 
ROBITET 
ROBITUSSIN 
SECTRAL 
SELEGILINE 
SEMICID 
SERAX 
SODIUM CHL 
SONATA 
SPARINE 
SPIRONOLAC 
STORZ-DEXA 
STUART PRE 
STUARTNATA 
SULFAMETHO 
SULFASALAZINE 
SULINDAC 
SUPRAX 
SURMONTIL 
SYNALGOS 
TEMAZEPAM 
TENEX 
TETANUS PI 
THEOPHYLLINE 
THIAMINE H 
THIORIDAZINE 
THYROID 
EXHIBIT A 
TOBRAMYCIN 
TODAY SPONGE 
TOLAZAMIDE 
TOLBUTAMIDE 
TRAZODONE 
TRI-IMMUNO 
TR1PHASIL 
TUBERCULIN 
TUBEXINJ 
TYGACIL IN 
UNIPEN 
VANCOLED 
VANCOMYCIN 
VERAPAMIL 
VIOKASE 
WYAMYCIN 
WYCILLIN 
WYDASE 
WYGESIC 
WYMOX 
WYTENSIN 
Z-BEC 
ZEBETA 
ZIAC 
IZOSYN 
"~1 
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